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ABSTRACT 
EARLY DIAGNOSIS OF PULMONARY EMBOLISM: 
REVIEW AND COST-EFFECTIVENESS ANALYSIS 
Efstathios Polychronopoulos 
Old Dominion University 
Director: Dr. Anna H. Jeng 
Pulmonary embolism (PE) is a serious, life-threatening thrombotic disease, which 
results in considerable health and economic consequences each year for the United 
States. These consequences include a toll of 83,000 deaths and an economic impact 
between $1.5 and $5 billion. Approaches to strategy selection by physicians and other 
health-care specialists are based mainly upon cost, technology availability, and cultural 
tolerance regarding radiation exposure. The purpose of this study was to determine the 
most cost-effective diagnostic strategy with patients suspected of PE among several 
strategies currently used by examining their detection failure rates. This objective was 
met by (a) assessing parameter estimates and their uncertainty using triangular and y 
distributions, (b) conducting a cost-effectiveness analysis, and (c) testing the model for 
errors using sensitivity analysis. 
Cost-effectiveness analysis based upon a decision tree model revealed that among 
the investigated strategies for patients with suspected PE the most cost-effective strategy 
appears to be strategy 3, composed of a clinical decision rule (CDR), a D-dimer test 
(DD), a compression ultrasonography test (CUS), and a computed tomography 
pulmonary angiography (CT). Strategy 5, composed by a CDR, DD, a CT, a CUS, and an 
invasive pulmonary angiography (PA) appeared to be a cost-effective method, but it was 
more expensive than strategy 3 and included an invasive pulmonary angiography (PA). 
The results of a Monte Carlo simulation sensitivity analysis were robust over a 
number of distributions regarding the PE diagnostic test costs, sensitivities, specificities, 
and strategy effectiveness. Additionally, the results of this investigation were valid over 
an extensive range of one-way, two-way, and three-way sensitivity analyses regarding PE 
diagnostic test costs. Overall, the proposed analyses identified uncertainty and eliminated 
error; thus, it provides a practical approach to help medical professionals estimate 
uncertainty in the diagnosis of PE. Although this research has broadened the ability to 
identify uncertainty and eliminate error, further research is needed to validate these 
findings in a prospective clinical trial before the delivery of a clinical recommendation. 
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Pulmonary embolism (PE) is a serious, life-threatening thrombotic disease, which 
results in considerable health and economic consequences each year for the United 
States. These consequences include a toll of 83,000 deaths and an economic impact 
between $1.5 and $5 billion (Anderson et al., 1991; Dobesh, 2009; Eichinger et al., 2004; 
Goldhaber, 2004; Heit, 2006, 2008; Heit, Mohr, et al., 2000; Kniffin, Baron, Barrett, 
Birkmeyer, & Anderson, 1994; MacDougall, Feliu, Boccuzzi, & Lin, 2006; Silverstein et 
al., 1998; Spyropoulos & Lin, 2007; Stein, Kayali, & Olson, 2004a; U.S. Department of 
Health and Human Services, 2008). PE incidence approximates 207,000 cases per year in 
the United States, the vast majority of which require hospitalization and expensive 
treatment (De Lissovoy & Subedi, 2002; Dobesh, 2009; MacDougall et al., 2006; 
McGarry, Thompson, Weinstein, & Goldhaber, 2004; Ollendorf, Llonch, & Oster, 2002; 
Silverstein et al., 1998; Spyropoulos & Lin, 2007; U.S. Department of Health and Human 
Services, 2008). The cost of diagnostic management and treatment of an initial PE 
episode ranges between $9,500 and $16,700, whereas the diagnostic management and 
treatment of PE combined with deep vein thrombosis (DVT) costs approximately 
$25,000 (De Lissovoy & Subedi, 2002; Dobesh, 2009; MacDougall et al., 2006; McGarry 
et al., 2004; Ollendorf et al., 2002; Silverstein et al., 1998; Spyropoulos & Lin, 2007; 
U.S. Department of Health and Human Services, 2008). Survivors are affected for the 
rest of their lives, and those who experience an initial PE episode are at high risk for 
recurrent PE within 10 years with the highest risk occurring during the first year 
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(Douketis, Kearon, Bates, Duku, & Ginsberg, 1998; Eichinger et al., 2004; Heit, 2006; 
Heit, Mohr, et al., 2000; Spencer et al., 2008; Stein, Hull, & Raskob, 2000; White, 2003). 
PE diagnostic strategies have been developed based upon combinations of clinical 
decision rules and available laboratory and imaging PE diagnostic tests such as the (a) D-
dimer test, (b) computed tomography pulmonary angiography scan, (c) ventilation-
perfusion lung scan, (d) compression ultrasonography test, and (e) invasive pulmonary 
angiography test (Elias et al., 2004; Gibson et al, 2008; Hudson et al., 1996; Sostman et 
al., 2008; Stein et al., 2006; Toulon, Lecourvoiser, & Meyniard, 2009; Wells et al., 2000). 
The costs associated with these tests and rules, implemented as diagnostic strategies, or 
screenings, are continually being evaluated. Current cost-effectiveness analyses of PE 
screenings result in variable findings because of several combinations of these tests and 
rules employed in medical conditions to which they are applied. The factors of cost and 
effectiveness of each screening present constant challenges to physicians as they decide 
which diagnostic strategy to select for use with certain conditions (Doyle et al., 2004; 
Hull, Graham, Stein, Mah, & Butcher, 2001; Paterson & Schwartzman, 2001; Perrier, 
Mathieu, Francois, Nigel, & Bounameaux, 2003; Quiroz & Schoepf, 2005). 
Statement of the Problem 
PE is difficult to diagnose. Misdiagnosis or delay in PE detection can be fatal. It is 
estimated that 10% of all patients with symptomatic PE die within 60 minutes of onset, 
and 15% of diagnosed patients die within three months after diagnosis (Goldhaber, 
Visani, & De Rosa, 1999; Kearon, 2003). 
Although clinicians are responsible for accurate diagnoses and must use care in 
the application of the available technologies for PE diagnosis, their selection of 
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diagnostic strategies varies greatly (Le Gal, Righini, Sanchez, et al., 2006; Nijkeuter et 
al., 2007; Perrier et al., 2005; Stone et al., 2003; Wells et al., 2001). Approaches to 
strategy selection by physicians and other health-care specialists are based mainly upon 
cost, technology availability, and cultural tolerance regarding radiation exposure 
(Brenner & Hall, 2007; Kline, Courtney, Beam, King, & Steuerward, 2009; Perrier, 2007; 
Piazza & Goldhaber, 2009; Sodhi & Kaur, 2005). Determining the most cost-effective PE 
diagnostic screening strategy might ease the challenge to health-care professionals of 
selecting the most appropriate strategy with which to diagnose a patient with suspected 
PE and might provide insight regarding the variability among currently available 
strategies. 
Purpose of the Study 
The purpose of this study was to determine the most cost-effective diagnostic 
strategy among several strategies currently used with patients with suspected PE based 
upon the failure rates of the respective strategies. The ability to identify the most cost-
effective strategy may result in wider implementation of a particular strategy for PE 
detection that is less costly and more effective when compared to alternate strategies. 
Factors Influencing the Cost-Effectiveness Analysis (CEA) of Pulmonary Embolism 
Early Diagnosis 
CEA basics. 
A cost-effectiveness analysis (CEA) of PE diagnostic strategies is used to 
compare the cost and effectiveness of a reference strategy with available alternate 
strategies by assessing the value of each using specific units of cost and effectiveness 
(e.g., dollars spent per additional life gained, dollars spent per additional PE episode 
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avoided) (see Doyle et al., 2004; Fenwick, 2009a; Gold, 1996; Hull et al., 2001; Hunink 
& Krestin, 2002; Jan, 2009; Kaplan, 2006; Kastanioti, 2009; Kuntz, Fleischmann, 
Hunink, & Douglas, 1999; Muennig, 2008; Paterson & Schwartzman, 2001; Perrier et al., 
2003; Quiroz & Schoepf, 2005; Yeh, 2009). There are three very important elements of a 
CEA for PE diagnostic strategies: composition, costs, and effectiveness. The composition 
of each PE diagnostic strategy includes specific clinical decision rules (CDRs), D-dimer 
tests, and imaging tests for detecting PE (Doyle et al., 2004; Hull et al., 2001; Paterson & 
Schwartzman, 2001; Perrier et al., 2003; Quiroz & Schoepf, 2005). 
CEA of PE diagnostic strategies can be conducted from a third-party payer cost 
perspective or a societal cost perspective, depending upon the particular set of decision-
making interests. The third-party payer cost perspective considers the economic impact 
on the payer, and the societal cost perspective examines the economic impact of costs 
without regard to who initiates the costs or who finances the costs. Typically, CEAs of 
PE diagnostic strategies have been conducted with consideration to the third-party payer 
perspective, which includes only direct costs of PE diagnostic strategies such as 
laboratory tests or diagnostic tests, treatment, and hospitalization. A CEA from a societal 
perspective includes indirect costs (e.g., costs due to productivity loss, waiting or travel 
time, or other economic impact on patients and their families) and opportunity costs (e.g., 
costs of market competition, income, and taxes). This type of examination is rarely 
employed (see Doyle et al., 2004; Fenwick, 2009a; Gold, 1996; Hull et al., 2001; Hunink 
& Krestin, 2002; Jan, 2009; Kaplan, 2006; Kastanioti, 2009; Kuntz et al., 1999; Muennig, 
2008; Paterson & Schwartzman, 2001; Perrier et al, 2003; Quiroz & Schoepf, 2005; Yeh, 
2009). 
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Finally, the effectiveness of each PE diagnostic strategy reflects the performance 
of the entire strategy, including failure to detect a PE, which could result in another PE 
episode that might be fatal. The effectiveness of a PE diagnostic strategy is commonly 
measured by mortality or survival rates (Doyle et al., 2004; Fenwick, 2009a; Gold, 1996; 
Hull et al., 2001; Hunink & Krestin, 2002; Jan, 2009; Kaplan, 2006; Kastanioti, 2009; 
Kuntz et al., 1999; Muennig, 2008; Paterson & Schwartzman, 2001; Perrier et al., 2003; 
Quiroz & Schoepf, 2005; Yeh, 2009). 
Pulmonary embolism diagnostic costs. 
A PE diagnostic strategy is a procedure that combines CDR with laboratory tests 
and imaging tests that surpasses the accuracy of a clinical assessment conducted using 
only D-dimer or imaging tests (Le Gal, Righini, Sanchez, et al., 2006; Nijkeuter et al., 
2007; Perrier et al., 2005; Stone et al., 2003; Wells et al., 2001). PE diagnosis usually 
begins with a clinical assessment that includes CDR, history, physical examination, and 
instrumental examination followed by a D-dimer test and other imaging tests, if 
necessary (Daniel, Courtney, & Kline, 2001; Gibson et al., 2008; Goekoop et al., 2007; 
Le Gal, Righini, Roy, et al., 2006; Miniati et al., 2003; Nijkeuter et al., 2007; PIOPED 
Investigators, 1990; Sanson et al., 2000; Sonne, Kamphuisen, Van Mierlo, & Buller, 
2005; Stein et al., 2007; Stein & Henry, 1997; Stein et al., 2008; Wells et al., 2000; Wicki 
et al., 2001). 
The high PE incidence, combined with the high average cost for PE diagnostic 
management and treatment, generates substantial economic cost consequences of as 
much as $5 billion annually for the U.S. health-care system (De Lissovoy & Subedi, 
2002; Dobesh, 2009; Knight et al., 2005; MacDougall et al, 2006; McGarry et al., 2004; 
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Ollendorf et al., 2002; Spyropoulos & Lin, 2007). In general, the average cost for a PE 
episode appears to be greater than a DVT episode, mainly due to longer hospitalization 
and greater treatment and medical costs (Dobesh, 2009). It is estimated that in the United 
States the cost of a first PE episode ranges between $9,500 and $16,600. The cost of an 
initial DVT episode ranges between $7,700 and $10,800. Overall, the annual economic 
impact of VTE for the entire U.S. health care system reaches at least $1.5 billion 
(Dobesh, 2009). 
De Lissovoy and Subedi (2002) estimated median costs of initial PE, DVT, and 
PE with DVT at $6,424, $3,131, and $6,678, respectively. The median costs of each 
recurrent VTE event, each bleed event, and each recurrent VTE with bleed event were 
estimated at $5,736, $4,999, and $10,185, respectively. Applying these estimates to 
annual PE and DVT incidences in the United States (207,000 and 143,000, respectively) 
reveals an annual economic cost of $1.33 billion for PE and $0.45 billion for DVT. Thus, 
the total annual VTE economic cost for the entire nation is approximately $1.8 billion. 
According to a 2007 study (Spyropoulos & Lin, 2007), the average annual direct 
medical costs of a PE episode were $16,644 and about $10,804 for a DVT episode. The 
cost for a recurrent PE was $14,722 and $11,862 for a recurrent DVT. Applying these 
estimates to annual PE and DVT incidences in the United States (207,000 and 143,000, 
respectively) reveals direct medical costs of $3.4 billion for PE and $1.5 billion for DVT. 
The total annual VTE direct medical costs for the entire nation are approximately $5 
billion. 
MacDougall et al. (2006) studied a cohort of 26,958 patients to determine that the 
annual median total reimbursed cost was $18,901 for a PE episode, $17,512 for a DVT 
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episode, and $25,554 when both PE and DVT were present. Applying these cost amounts 
to annual PE and DVT incidences in the United States (207,000 and 143,000, 
respectively) reveals annual direct medical costs of $3.9 billion for PE and $2.5 billion 
for DVT. The total annual VTE reimbursed cost for the entire nation is approximately 
$5.4 billion. 
The Decision Tree Framework for Assessing Cost-Effectiveness 
A common decision-making theoretical framework used in previous studies to 
assess the cost-effectiveness of PE diagnostic strategies is the decision tree framework 
(Doyle et al., 2004; Muennig, 2008; Paterson & Schwartzman, 2001; Perrier et al., 2003; 
Quiroz & Schoepf, 2005). This theoretical framework offers a meaningful presentation of 
very complex decision-making problems by (a) overcoming the restriction of presenting 
data in a tabular format and (b) offering the advantages of outlining all potential actions, 
delineating all probable events, and demonstrating all possible outcomes (Lapin & 
Whisler, 2002). The decision tree framework is based upon three major concepts—act, 
event, and outcome—as described by Lapin & Whisler (2002) (see Figure 1). 
Act is defined as the decision maker's choices. In each decision, an initial action 
occurs. For example, when one must choose among four diagnostic strategies to detect a 
disease, each strategy represents a potential initial action. The decision tree framework 
demonstrates all actions on the left side of the tree's structure. 
An event is defined as the component of the decision that contains an element of 
uncertainty following an initial action. Probability values are assigned to each event in 
the decision tree structure, the sum of which equals 1.00. For example, with uncertainty 
regarding diagnostic test results from diagnostic strategy 1 (Action 1), two events can 
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occur: either the patient receives treatment or another test is administered. If the 
probability of receiving treatment is p, then the probability of the administration of 
another test is 1-p. 
A new action can follow an event. For example, after selecting the initial action of 
applying a diagnostic strategy (Action 1) and selecting another test (Event 2), the new 
action is the administration of another test, which creates a new event that presents a 
different element of uncertainty. In the decision tree framework, there is a chronological 
progression of events. Those indicated on the left side are assumed to occur before events 
indicated on the right side of the decision tree. 
Outcome is defined as any component that can be used to measure the 
investigating condition. A clear measure of an outcome is its payoff value in dollars per 
life saved. Using an example of disease detection, if the decision maker chooses to apply 
diagnostic strategy A, then the outcome will be $1.00 per life saved. If he or she selects 
diagnostic strategy B, then the payoff will be $1.50 per life saved. If diagnostic strategy 
A results in greater effectiveness but is more expensive than strategy B, then the outcome 
should be expressed in an incremental cost-effectiveness ratio of dollars per additional 
life saved. However, calculations that are more complicated follow when expressing an 
outcome in an incremental cost-effectiveness ratio of dollars spent per additional life 
saved. The decision tree framework demonstrates the outcomes or the consequences of 









Figure 1. Decision tree framework. A square represents a decision node. A circle 
represents a chance node. Several events can occur with corresponding outcomes under 
each action . For example, under Action 1, Events 1-lor 1-2 can occur with 
corresponding Outcomes 1-1 or 1-2, while under Action j , Events n-1 or n-2 can occur 
with corresponding Outcomes n-1 or n-2. 
Significance of the Study 
At the time of this dissertation limited research was available to identify the most 
cost-effective diagnostic strategy currently in use that detects PE. This study assessed the 
cost and effectiveness of several diagnostic strategies currently in use for patients with 
suspected PE. Specifically, this research attempted to determine the most cost-effective 
diagnostic strategy, particularly with attention to its screening value (i.e., screening 
failure rate). 
1
 The decision tree framework for assessing cost-effectiveness is based upon the decision tree framework as 
described by Lapin and Whisler (2002). 
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The individual cost and effectiveness components of PE detection, though 
significant, do not describe the combined effect of the performance and the economic 
impact of a PE diagnostic strategy compared to alternate strategies. When a PE diagnostic 
strategy results in better effectiveness, but costs more than an alternate strategy, the 
incremental cost-to-incremental effectiveness ratio (ICER) should be calculated. 
Therefore, this study examined the combined effect of performance and economic impact 
of costs and effectiveness with particular attention to the failure rates of each diagnostic 
strategy for detecting PE. 
This study is one of only a few studies, which have investigated factors 
influencing PE diagnostic strategies from a cost-effectiveness perspective. This study is 
the only study that has addressed these strategies using a CEA in combination with 
triangular distributions, y distributions, and Monte Carlo Simulation to evaluate which PE 
diagnostic strategy is more cost-effective based upon the failure rates for PE detection. 
Assumptions 
A few assumptions were made about diagnostic tests, treatment, and utilization of 
secondary data. First, if PE is ruled out, then patients will not receive treatment or further 
tests. Additionally, if PE is confirmed, then patients will receive treatment, and no further 
tests will be performed. Also, if PE is not ruled out or confirmed, then further imaging 
test(s) will follow. Finally, it was assumed that the secondary data identified in literature 
are true and unbiased. 
Limitations 
Several limitations can be applied to this study. First, this research is based upon 
data collected solely from the literature cited, which limits the applicability of the data to 
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the design and methodology presented in the original research. In addition, it is assumed 
that all tests included in the investigated strategies are available and that any strategy 
could be selected based upon the cost-effectiveness analysis (CEA). This analysis 
approached the implementation of treatment and the nondiagnostic imaging test results in 
the same manner that they were approached in the cited literature. Further, this study did 
not distinguish between different types of the same imaging test because it is focused 
upon early PE diagnosis in patients, in general, and not upon an evaluation of each of the 




This chapter reviews the literature that addressed this study's components: a 
theoretical decision-making framework, individual screening tools for diagnosing 
pulmonary embolism (PE), their combinations into distinct diagnostic strategies, and 
cost-effectiveness analysis (CEA) studies of these strategies. The decision tree 
framework (Lapin & Whisler, 2002) is described, and its application to a CEA for 
assessing PE diagnostic strategies is presented. 
PE is a serious disease. It is difficult to diagnose and it has considerable health 
and economic impacts on a community (Dobesh, 2009; U.S. Department of Health and 
Human Services, 2008). Diagnostic challenges are mainly associated with the 
implementation of clinical decision rules, the availability of diagnostic laboratory and 
imaging tests, and the medical costs associated with them (Brenner & Hall, 2007; Kline, 
Courtney, Beam, King, & Steuerward, 2009; Perrier, 2007; Piazza & Goldhaber, 2009; 
Sodhi & Kaur, 2005). The application of cost-effective diagnostic strategies could reduce 
costs and decrease mortality and recurrence rates of the disease in patients with suspected 
PE (Horlander, Mannino, & Leeper, 2003; Perrier, 2007; Stein, Kayali, & Olson, 2004a). 
Theoretical Framework: The Decision Tree Framework 
The theoretical framework for this study is based upon the comprehensive 
decision tree framework, as described by Lapin & Whisler (2002). It was selected for its 
flexibility in combining three constructs—Actions, Events, and Outcomes—of a decision 
and for its use in previous studies that evaluated the cost- effectiveness of PE diagnostic 
strategies (Doyle et al., 2004; Paterson & Schwartzman, 2001; Perrier, Mathieu, Francois, 
13 
Nigel, & Bounameaux, 2003; Quiroz & Schoepf, 2005). The PE diagnostic strategies 
were assigned to the Actions construct. The components of these strategies (i.e., the 
diagnostic tools that include clinical decision rules, laboratory tests, and imaging tests) 
were assigned to the Events construct. A probability value that the event will occur was 
assigned to each Events construct. The supposition of a payoff was assigned to the 
Outcomes construct. 
The Actions construct includes the PE diagnostic strategies investigated in this 
study. Diagnostic strategy is defined as a series of diagnostic procedures based upon a 
combination of clinical decision rules (CDR), laboratory tests, and imaging tests that can 
maximize the accuracy of a stand-alone clinical decision rule, D-dimer test, or imaging 
test performed to detect a disease. First, patients are evaluated for PE by a clinical 
decision rule. If PE is not excluded, then a D-dimer test is administered. If PE still is not 
excluded, then an imaging test or tests are performed to rule out or confirm PE (see 
Doyle et al., 2004; Hull, Graham, Stein, Mah, & Butcher, 2001; Paterson & 
Schwartzman, 2001; Perrier et al., 2003; Quiroz & Schoepf, 2005). 
The Events construct includes clinical decision rules (CDR) used to detect a 
disease. A CDR is defined as "an instrument containing variables obtained from history, 
physical examination, and simple diagnostic tests, quantifying the likelihood of a 
diagnosis, prognosis, or likely response to treatment in an individual patient" (Klok et al., 
2008, p. 2131). The Events construct also includes the diagnostic tests performed to 
detect a disease. A diagnostic test is defined as the laboratory or imaging test applied to 
detect a disease (Elias, Colombier, et al., 2004; Hudson et al., 1996; Sostman, Stein, et 
al., 2008; Stein, Fowler, et al., 2006; Toulon et al., 2009). The D-dimer test (DD) is a 
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laboratory blood test used to exclude PE and to eliminate the need for imaging testing 
(Hogg et al., 2005; Kline, Runyon, Webb, Jones, & Mitchell, 2006; Stein, 2007a; Stein, 
Hull, et al., 2004). Imaging tests are diagnostic tests based upon a range of imaging 
modalities to diagnose a disease (Elias, Colombier, et al., 2004; Hudson et al., 1996; 
Perrier, 2007; Perrier et al., 2005; Sostman, Stein, et al., 2008; Stein, Fowler, et al., 2006; 
Toulon et al., 2009). Several different imaging tests can be performed to detect PE. These 
include a computed tomography pulmonary angiography (CT), a ventilation-perfusion 
lung scan (VQ), a compression ultrasonography (CUS), and an invasive pulmonary 
angiography (PA). Also included in this construct is the probability that a test will 
exclude (rule out) or confirm PE and the probability that a new (i.e., additional) test will 
follow (Doyle et al., 2004; Hull et al., 2001; Paterson & Schwartzman, 2001; Perrier et 
al., 2003; Quiroz & Schoepf, 2005). 
The Outcomes construct includes any payoff for each event. The payoff in this 
study was defined as the combined cost and effectiveness of each event (Doyle et al., 
2004; Hull et al., 2001; Paterson & Schwartzman, 2001; Perrier et al., 2003; Quiroz & 
Schoepf, 2005). Accordingly, direct costs are defined as "Costs associated with goods 
and services consumed", and effectiveness is defined as "The performance of health 
intervention in the real world" (Muennig, 2008, p. 250). 
The basic tenet of the decision tree framework, also well-known as decision tree 
model, is that events are presented in a chronological sequence. Events indicated on the 
left side of the framework occur before events on the right side of the framework, 
beginning with the event node at the furthest left (Doyle et al., 2004; Ishwaran & Rao, 
2009; Lapin & Whisler, 2002; Paterson & Schwartzman, 2001; Perrier et al., 2003; 
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Sonnenberg & Hagerty, 2009). The initial component of the decision tree framework is 
the decision node, usually depicted by a small square with at least two lines originating 
from it that represent possible options. In this study, the lines beginning at the decision 
node symbolized the available PE diagnostic strategies as options. 
The next component of a decision tree framework is the chance node, usually 
depicted by a small circle. Several lines originate from each chance node, which 
represents the possible events that cannot be controlled by the decision maker, for 
example, laboratory test results. Assume that the implementation of strategy 1 included a 
D-dimer test. If the test results are negative, then no treatment will be administered; if the 
test results are positive, then a CT will be performed. Regardless, the decision maker has 
no control or foreknowledge of the event's results. 
The probabilities for a single event in this study are (a) the probability of a test to 
rule out or confirm PE and (b) the probability of a new (i.e., additional) test to follow. 
For example, if the probability that a D-dimer test is negative is 0.30, then the probability 
that an additional test will follow is 0.70 because the summing of the event's probabilities 
must equal 1.00. The last component of a decision tree framework is the payoff, the 
triangle at the far right side of the decision tree, which began at a decision node that was 
followed by a chance node in the Actions and Events constructs. Payoffs are the 
consequences of the events. In this study, a payoff was described as the 3-month follow-
up mortality rates and the VTE (i. e., PE and/or DVT) recurrence rates occurring among 
patients with suspected PE after the implementation of a certain diagnostic test or a series 
of tests with their corresponding costs. Figure 2 depicts a decision tree framework for 
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Figure 2. Decision tree framework for PE diagnostic strategies. A square represents a 
decision node. A circle represents a chance node. A triangle represents a terminal node. 
Several events can occur with corresponding probabilities and outcomes under each 
action2. For example, under Action PE diagnostic strategy 1, Event PE test li or 12 . . . ln 
can occur with corresponding Probabilities 11 or 1 2 . . . ln and Outcomes payoff 11 or 1 2 . . 
. ln, while under ActionVE diagnostic strategy },EventVE test ji or j 2 . . . j n can occur 
with corresponding Probabilities ji or j 2 . . . j n and Outcomes payoff ji or j 2 . . . j n . 
2
 The decision tree framework for PE diagnostic strategies is based upon the decision tree 
framework as described by Lapin and Whisler (2002). 
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Pulmonary Embolism Diagnostic Tools 
A review of the literature was conducted to identify diagnostic tools for PE 
screening currently in use. Identified diagnostic tools included clinical decision rules, D-
dimer tests, and imaging tests such as computed tomography pulmonary angiography 
(CT), ultrasonography (CUS), ventilation-perfusion lung scan (VQ) and invasive 
pulmonary angiography (PA). This review highlights CDR scoring systems as well as D-
dimer and imaging test sensitivity and specificity values to detect PE in patients with 
suspected PE. 
In this study, sensitivity was defined as the percentage of patients with PE who 
obtained a positive test result. Conversely, specificity was defined as the percentage of 
patients without PE who obtained a negative test result. Additionally, five sensitivity and 
specificity levels were established: very low with a value of less than 60%, low with a 
value between 60 and 79.99%, moderate with a value between 80 and 89.99%, high with 
a value between 90 and 95.99%, and very high with a value between 96 and 100%. A test 
with very high sensitivity/low specificity or low sensitivity/very high specificity values 
was considered a poorly performing test. Only a test demonstrating both very high 
sensitivity and very high specificity values was considered an excellent test. 
Clinical decision rules. 
Historically, PE detection has been empirically based upon the patient's medical 
history and a physical examination. However, during the past decade several clinical 
decision rules (CDRs) have been introduced that use a scoring system, which measures 
the pretest probability of PE with certain clinical variables (Klok et al., 2008). In 
particular, during the past decade, seven CDRs for PE detection currently in use have 
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been identified and discussed in the literature: (a) the extended Wells CDR (Wells et al., 
2000); (b) the simplified Wells CDR (Gibson et al., 2008); (c) the original Geneva CDR 
(Wicki et al., 2001); (d) the revised Geneva CDR (Le Gal et al., 2006); (e) the Pisa CDR 
(Miniati et al., 2003); (f) the Pennsylvania CDR (Aujesky et al 2005); and (g) the 
Charlotte CDR (Kline et al., 2002). A brief presentation of each CDR follows. 
Extended and simplified Wells CDRs. The extended Wells CDR and the 
simplified Wells CDR are Canadian clinical models (Gibson, Sonne, et al., 2008; Wells 
et al., 2000) based upon standardized scores, the maximum of which are 12.5 and 7, 
respectively. Wells CDRs include the following seven clinical variables: clinical signs 
and symptoms of DVT, heart rate higher than 100 beats per minute, immobilization or 
surgery in the past four weeks, previous PE or DVT episode, hemoptysis, cancer, and an 
alternative diagnosis is less likely than a PE diagnosis. There are two main differences 
between the extended and simplified Wells CDRs. First, in the extended CDR, a score of 
3 is assigned for two variables; a score of 1.5 is assigned for three variables; and a score 
of 1 is assigned for two variables resulting in a maximum score of 12.5. In the simplified 
CDR, the same score of 1 is assigned to all seven variables resulting in a maximum score 
of 7. Second, PE is considered unlikely if the total score is 4 or less in the extended CDR 
and 1 or less in the simplified CDR. In the extended Wells CDR, a total score of less than 
2 represents a low clinical probability of PE, while a score between 2 and 6 signifies a 
moderate clinical probability of PE, and a score greater than 6 indicates a high clinical 
probability of PE. 
Original and revised Geneva CDRs. The original Geneva CDR is a clinical 
model based upon a scoring system of clinical variables combined with an arterial blood 
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gas analysis, while the revised Geneva CDR is a scoring system with clinical variables 
without a blood gas analysis (Le Gal, Righini, Roy, et al., 2006; Wicki et al., 2001). The 
level of probability for PE in the original Geneva CDR is based upon a total score 
achieved by combining scores assigned to clinical variables and blood gas analysis. A 
score of 0 to 4 indicates a low clinical probability of PE; a score of 5 to 8 signified a 
moderate clinical probability of PE; and a score of 9 or higher represents a high clinical 
probability of PE (Wicki, Perneger, Junod, Bounameaux, & Perrier, 2001). Similarly, in 
the revised Geneva CDR, a score of 0 to 3 indicates a low clinical probability of PE; a 
score of 4 to 10 represents a moderate clinical probability of PE; and a score of 11 or 
higher denotes a high clinical probability of PE (Le Gal, Righini, Roy, et al., 2006). 
Clinical probability levels for PE for the extended Wells, simplified Wells, original 
Geneva, and revised Geneva CDRs are presented in Table 1. 
Table 1 
Clinical Probability Levels for PE of the Wells and Geneva CDR Scoring Systems 
Clinical Probability Levels for PE Study 
Low, moderate, high Unlikely, Likely First Author & Year 
Extended Wells CDR Extended Wells CDR Wells, 2000 
Simplified Wells CDR Simplified Wells CDR Gibson, 2008 
Original Geneva CDR Wicki, 2001 
Revised Geneva CDR Le Gal, 2006 
Note. PE = pulmonary embolism; CDR = clinical decision rule. 
Pisa, Pennsylvania, and Charlotte CDRs. In 2003, Miniati, Monti, and Bottai 
proposed a clinical model to predict PE (Pisa CDR) that included 10 variables associated 
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with a high risk of PE and five variables associated with a low risk of PE (Miniati, Monti, 
& Bottai, 2003). High-risk indicators include, but are not limited to, male gender, older 
age, sudden-onset dyspnea, chest pain, and hemoptysis. According to the Pisa CDR, the 
clinical probability of PE is classified into four distinct categories: low (score of less than 
or equal to 10%), intermediate (score of greater than 10% to less than or equal to 50%), 
moderate (score of greater than 50% to less than or equal to 90%), and high (score of 
greater than 90%). The implementation of this model demonstrated excellent accuracy in 
predicting PE, specifically, the classification into the high-risk group of 28% of the 
patients, 98% of whom were accurately diagnosed with PE. Although the Pisa CDR 
revealed excellent results, it has the major disadvantage of difficult implementation 
(Miniati et al., 2003; Stein, 2007b). 
In 2005, Aujesky and colleagues conducted an analysis of 15,531 hospital 
discharges of PE patients from 186 Pennsylvania hospitals that used a PE diagnosis CDR 
of 11 variables, which categorized patients into five risk classes (Aujesky et al., 2005). 
According to this CDR, a score of less than or equal to 65 indicates very low risk (Class 
I); a score of 66 to 85 inclusive suggests low risk (Class II); a score of 86 to 105 inclusive 
denotes intermediate risk (Class III); a score of 106 to 125 inclusive signifies high risk 
(Class IV); and a score above 125 represents very high risk (Class V). In a follow-up 
study, the researchers concluded that this CDR is useful in identifying low-risk patients 
with PE (Aujesky et al., 2006). 
The Charlotte CDR proposed by Kline and colleagues (2002) is a flow protocol to 
rule out PE based upon specific criteria in combination with the use of a D-dimer test 
(Kline, Nelson, Jackson, & Courtney, 2002). The criteria include (a) suspicion for PE; (b) 
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the shock index (heart rate divided by systolic blood pressure) greater than 1 or the 
patient age is greater than 50; (c) non-smoker, no asthma, no COPD, or unexplained 
hypoxemia (Sa02 less than 95%); (d) unilateral leg swelling; (e) recent surgery; and (f) 
hemoptysis (Kline et al., 2002; Kline & Wells, 2003). Although accurate, the Charlotte 
CDR is disadvantaged by the complexity of its variables, scoring, classifications, and its 
D-dimer test requirement (Kline et al., 2002; Kline, Webb, Jones, & Hernandez-Nino, 
2004; Kline & Wells, 2003; Runyon, Webb, Jones, & Kline, 2005). 
D-dimer tests. 
There are several types of D-dimer tests (DD) available, including (a) enzyme 
linked immuno-sorbent assay (ELISA), (b) ELISA rapid quantitative, (c) ELISA rapid 
semi-quantitative, (d) latex quantitative agglutination assay, (e) latex semi-quantitative 
agglutination assay, (f) whole-blood agglutination assay, and (g) simplify D-dimer assay. 
The time-to-results for these tests are approximately 8 hours, 35 minutes, less than 10 
minutes, 7 to 15 minutes, 3 to 4 minutes, 2 minutes, and about 10 minutes, respectively 
(Bruinstroop, van de Ree, & Huisman, 2009; De Moerloose et al., 2008; Di Nisio et al., 
2007; Ghanima & Sandset, 2007; Hogg et al., 2005; Kline et al., 2006; Parent et al., 
2007; Stein, 2007a; Than et al., 2009; Toulon et al., 2009; van Belle et al., 2006). 
Although D-dimer tests have been used since the 1980s, their contribution to PE 
diagnosis is controversial, particularly regarding their sensitivity and specificity values. A 
negative D-dimer test for patients with either low or moderate clinical probability of PE 
safely rules out PE, while a positive D-dimer test is nonspecific (Stein, 2007a). 
The sensitivity and specificity levels of several D-dimer assays derived from 
studies published between 2004 and 2009 are presented in Table 2. 
Table 2 
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Stein, 2004 






Di Nisio, 2007 
Than, 2009 
Stein, 2004 









Note. ELISA = enzyme linked immuno-sorbent assay; Simplify = whole-blood agglutination D-dimer 
assay; VIDAS = rapid quantitative ELISA D-dimer assay; STA-Liatest = Diagnostica Stago Liatest latex 
rapid quantitative agglutination D-dimer assay. M = moderate sensitivity level with a value between 80 and 
89.99%; H = high sensitivity level with a value between 90 and 95.99%; VH = very high sensitivity level 
with a value between 96 and 100%; VL= very low specificity level with a value less than 60%; L = low 
specificity level with a value between 60 and 79.99%. 
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Computed tomography pulmonary angiography. 
Computed tomography pulmonary angiography (CT) is a combination of X-ray 
and computer images providing cross-sectional views of organs and tissues of a patient 
(Brenner et al., 2007; Odle, 2006). "In helical CT, which is commonly used for body 
scans, the table moves continuously as the x-ray source and detectors rotate, producing a 
spiral or helical scan" (Brenner et al., 2007, p. 2279). CT scanning systems currently in 
use are single or multiple-row (also called multiple-slice) systems. 
Early in the 1990s, the noninvasive and quick CT emerged with great potential for 
PE detection. Since then, as the number and speed of CT detectors have increased and the 
sensitivity and specificity values have improved, CT has become the imaging technique 
of choice for PE diagnosis (Perrier et al., 2005). Several systematic reviews have 
collectively chronicled the technological improvements in CT (Eng et al., 2004; Rathbun, 
Whitsett, Vesely, & Raskob, 2004; Roy et al., 2005; van Beek, Brouwers, Bing, 
Bongaerts, & Oudkerk, 2001; Van Rossum et al., 1996). In 2002, a sensitivity of 91% 
and a specificity of 94% were reported for CT (Nilsson et al., 2002). 
According to reviews and meta-analyses published between 2000 and 2006, CT 
demonstrated summary sensitivities ranging from 79 to 89% and summary specificities 
ranging from 89 to 95% (Cueto, Cavanaugh, Benenson, & Redclift, 2001; Harvey, 
Gefter, Hrung, & Langlotz, 2000; Hayashino, Goto, Noguchi, & Fukui, 2005; Hogg, 
Brown, et al., 2006; van Beek et al., 2001). The investigators in the large PIOPED II 
study, which used 4-, 8-, and 16-multidetector-row CT scanners, reported a sensitivity of 
83%> and a specificity of 96% for PE (Stein, Fowler, et al., 2006). In 2009, Wang and 
colleagues established a sensitivity of 91.7% and a specificity of 100% with 16- or 64-
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multidetector-row CT for PE (Wang et al., 2009). CT is an adequate test and is 
considered by several researchers as the new, diagnostic gold standard for PE detection, 
despite the challenges of detecting pulmonary embolisms at the small vessel level, a 
common hurdle for all PE diagnostic tests (Goodman & van Beek, 2009; Mos et al., 
2009; Quiroz et al., 2005). 
Compression ultrasonography. 
Compression ultrasonography (CUS) is an imaging test appropriate for PE 
detection. Its diagnostic validity is based upon the lack of compressibility of a venous 
segment. There are three CUS techniques: (a) segmental compression CUS of the 
common femoral and popliteal veins; (b) extended compression CUS of the complete 
deep thigh and popliteal veins; and (c) complete compression CUS of all segments of the 
deep thigh and calf veins (Beyer et al., 2007). 
CUS of the veins in the lower limbs is usually performed following a D-dimer test 
or a VQ lung scan to detect indirectly PE in patients with suspected PE. The CUS is 
performed because PE and DVT in a lower limb (i.e., leg) are considered conditions 
related to the same disease, and DVT is present in about 30% of all patients with PE 
(Elias et al., 2005; Elias, Colombier, et al., 2004; Galle et al., 2001; Kalva, Jagannathan, 
Hahn, & Wicky, 2008; Kearon & Ginsberg, 1998; Le Gal, Righini, Sanchez, et al., 2006; 
Michiels et al , 2005; Paterson & Schwartzman, 2001; Perrier, 2007; Perrier et al., 2003; 
Perrier et al., 2004; Quiroz et al., 2005; Righini et al., 2008; Righini et al., 2009; Turkstra 
etal., 1997). 
CUS sensitivity levels have been reported as low as 50% with a range of 30 to 
60% and a specificity of 95 to 100% (Perrier, 2007; Perrier et al., 2003) to as high as 
25 
82.4% with a range of 50 to 90% and a specificity of 86 to 100% (Paterson & 
Schwartzman, 2001). A sensitivity of 93% and a specificity of 84% were reported for a 
CUS of proximal and distal veins to detect PE (Elias, Colombier, et al., 2004). In 2006, 
Le Gal and colleagues determined a sensitivity of 39% and a specificity of 99% for CUS 
investigating the presence of PE (Le Gal, Righini, Sanchez, et al., 2006). More recently, 
Righini and colleagues revealed a poor sensitivity of 22% and a high specificity of 94% 
for CUS in PE detection (Righini et al., 2009). 
Although studies of CUS sensitivity and specificity have indicated variability 
within those two determinants, CUS presents some advantages for PE detection (Elias et 
al., 2005; Galle et al., 2001; Michiels et al., 2005; Perrier et al., 2004; PIOPED 
Investigators, 1990; Quiroz et al., 2005). First, CUS is useful as a diagnostic tool 
subsequent to a nondiagnostic VQ lung scan or nondiagnostic CT (PIOPED Investigators, 
1990). For instance, a positive CUS subsequent to a nondiagnostic VQ lung scan can 
confirm PE (PIOPED Investigators, 1990). Also, the combination of a negative CUS and 
a negative CT can rule out PE (Elias et al., 2005; Perrier et al., 2004; Quiroz et al., 2005). 
Second, CUS can help reduce the total number of patients requiring additional imaging 
tests (Elias et al., 2005; Michiels et al., 2005; Perrier et al., 2004; Quiroz et al., 2005). 
Third, an advantage of its ease of use, practicality, and accessibility is its application as a 
bedside test with intensive care patients (Galle et al., 2001). 
Ventilation-perfusion lung scan. 
A ventilation-perfusion lung scan (VQ) comprises two imaging procedures: 
perfusion and ventilation. Perfusion evaluates the blood flow in the lungs, and ventilation 
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assesses the air space distribution in the lungs (Dutton et al., 2009). There are two main 
VQ techniques in use, the traditional PLANAR VQ and the SPECT VQ. 
During the 1980s and 1990s, VQ lung scan was the dominant diagnostic tool for 
suspected PE (see Bajc & Jonson, 2009; Bajc et al., 2009a; Bajc, Olsson, Olsson, Palmer, 
& Jonson, 2004; Cook & Kyriou, 2005; De Geeter, Reinartz, & Buell, 2005; Douma, 
Kamphuisen, Rijnders, Ten Wolde, & Biiller, 2009; Einstein, Henzlova, & Rajagopalan, 
2007; Freeman & Haramati, 2009; Freeman, Stein, Sprayregen, Chamarthy, & Haramati, 
2008; Gutte et al., 2010; Gutte et al., 2009; Hull, Raskob, Coates, & Panju, 1990; Itti et 
al., 2002; Meignan, 2002; Parker et al., 2005; Perrier, 2007; Reinartz et al., 2004; Roach, 
Thomas, Bajc, & Jonson, 2008; Scarsbrook, Bradley, & Gleeson, 2007; Sostman, 
Miniati, et al., 2008; Sostman, Stein, et al., 2008; Stein et al., 2009; Stein, Kayali, & 
Olson, 2004b; Stein, Woodard, et al., 2006; Uren, 2009; Zophel, Bacher-Stier, Pinkert, & 
Kropp, 2009). However, after the publication of the PIOPED I (Prospective Investigation 
of Pulmonary Embolism Diagnosis I) in 1990, a controversy ignited about the accuracy 
of the VQ lung scan due to low sensitivity and substantial numbers of nondiagnostic 
results. 
This controversy continued after the publication of the PIOPED II (Prospective 
Investigation of Pulmonary Embolism Diagnosis II) in 1996, and although significant 
improvements were made in the interpretation of VQ lung scans, this controversy 
continues (Bajc et al., 2004; De Geeter et al., 2005; Douma, Kamphuisen, et al., 2009; 
Freeman et al., 2008; Gutte et al., 2010; Meignan, 2002; Perrier, 2007; Reinartz et al., 
2004; Roach et al., 2008; Sostman, Stein, et al., 2008; Stein et al., 2009; Uren, 2009). 
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A high-probability VQ lung scan indicates the presence of PE; normal- or low-
probability results indicate the absence of PE. Using the results of the PIOPED I study, 
Perrier (2007) reported a sensitivity of 99% for normal-probability VQ lung scans and a 
specificity of 91% for high-probability VQ lung scans for PE. From the PIOPED II study 
results, Sostman, Stein, and colleagues (2008) reported a sensitivity of 77.4% for high-
probability VQ lung scans and a specificity of 97.7% for normal- or low-probability VQ 
lung scans. None of the VQ lung scans was nondiagnostic. 
Comparisons of the tomographic ventilation-perfusion lung imaging (SPECT VQ) 
to traditional planar ventilation-perfusion lung imaging (Planar VQ) indicated that the 
SPECT VQ is a more accurate tool for diagnosing PE (Bajc et al., 2004; De Geeter et al., 
2005; Douma, Kamphuisen, et al., 2009; Freeman et al., 2008; Gutte et al., 2010; 
Meignan, 2002; Perrier, 2007; Reinartz et al., 2004; Roach et al., 2008; Sostman, Stein, et 
al., 2008; Stein et al., 2009; Uren, 2009). In 2004, greater sensitivity and specificity for 
the SPECT VQ than for the Planar VQ in PE detection were reported (Bajc et al., 2004; 
Reinartz et al., 2004). More recently, it was corroborated that the SPECT VQ had a 
greater sensitivity (100%) and specificity (87%) than did the Planar VQ (64% and 72%, 
respectively) (Gutte et al., 2010). 
Invasive pulmonary angiography. 
Invasive pulmonary angiography (PA) is the most accurate procedure for 
diagnosing PE and served as the diagnostic gold standard for many decades. It has a very 
high sensitivity of 96% and a very high specificity of 97%, but it is no longer widely used 
by physicians because of its expense and, more importantly, its invasiveness, which has 
associated risks with complications at a rate of 1 to 5% and mortality at a rate of up to 
28 
0.5%, inclusive (Hudson et al., 1996; Paterson & Schwartzman, 2001; Perrier, 2007; 
PIOPED Investigators, 1990; Stein et al., 1992; van Loveren, van Beek, & Oudkerk, 
2009). 
PA complications during the 1960s, 1970s, and 1980s occurred at an average rate 
of 2.1%) (see Mills, Jackson, Older, Heaston, & Moore, 1980; Nilsson, Carlsson, & Mare, 
1998; Oudkerk et al., 2002; van Beek, Brouwers, Song, Stein, & Oudkerk, 2001; van 
Loveren et al., 2009). Complication rates dropped in the 1990s to an average of 0.62%, 
due to technological advances such as the development of a safer catheter and rapid 
imaging equipment improvements (see Hudson et al., 1996; Nilsson et al., 1998; Stein et 
al., 1992; Stein, Sostman, et al., 2008; van Beek, Reekers, Batchelor, Brandjes, & Biiller, 
1996; van Loveren et al., 2009). Currently, non-fatal complication rates have dropped as 
low as 0.3 to 0.5%) and as low as 0.03% for fatal complications (see Nilsson et al., 1998; 
Stein, Sostman, et al., 2008; van Loveren et al., 2009). 
Today, PA remains important as the final diagnostic tool for specific categories of 
patients with suspected PE for whom noninvasive methods produce nondiagnostic results 
or for whom interventions are under consideration (see Hudson et al., 1996; Paterson & 
Schwartzman, 2001; Perrier, 2007; PIOPED Investigators, 1990; Qanadli et al., 2000; 
Stein et al., 1992; van Loveren et al., 2009; Winer-Muram et al., 2004). 
Pulmonary Embolism Diagnostic Strategies 
Various PE diagnostic strategies that combine the diagnostic components of CDR, 
DD, CT, VQ, CUS, and/or PA were identified in the literature. Each of the PE diagnostic 
strategies identified in this review includes a CDR as well as a DD. Each strategy was 
identified either as independent or as a branch of a strategy that could be subsumed into 
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one of five categories. The composition of the 14 identified diagnostic strategies is 
presented in Table 3. 
Table 3 









































































Note. PE = pulmonary embolism; CDR = clinical decision rule; DD = D-dimer test; CT = computed 
tomography pulmonary angiography; CUS = compression ultrasonography; VQ = ventilation-perfusion 
lung scan; PA = invasive pulmonary angiography. 
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Clinical decision rule and D-dimer test. 
Strategy 1 comprises a combination of the clinical decision rule (CDR) and the D-
dimer test (DD) as components for assessing pulmonary embolism in patients. Patients 
are evaluated first with a CDR followed by a DD. Studies suggest that PE can be safely 
ruled out in patients with a low clinical probability of PE and a negative DD, which is the 
outcome in 24 to 47% of the patients with suspected PE. Patients with a moderate or high 
clinical probability of PE and a positive DD usually undergo further diagnostic tests (see 
Carrier et al., 2009; Corwin, Donohoo, Partridge, Egglin, & Mayo-Smith, 2009; Djurabi 
et al., 2009; Gibson, Sohne, Gerdes, et al., 2008; Gupta, Kakarla, Kirshenbaum, & 
Tapson, 2009; Hammond & Hassan, 2005; Kabrhel et al., 2009; Kearon et al., 2006; 
Kruip, Slob, Schijen, van der Heul, & Biiller, 2002; Pasha et al., 2009; Perrier et al., 
2005; Righini et al., 2006; Rodger et al., 2006; Segal, Eng, Tamariz, & Bass, 2007; 
Soderberg, Brohult, Jorfeldt, & Larfars, 2009; Stein, Hull, et al., 2004; Teismann, 
Cheung, & Frazee, 2009; van Belle et al., 2006; Wells et al., 2000; Wells et al., 2001). 
There are concerns regarding the accuracy of this diagnostic strategy for the 
elderly, mostly because DD levels increase with age (Righini, Goehring, Bounameaux, & 
Perrier, 2000). There are also concerns regarding its accuracy with pregnant women 
because DD levels are higher in pregnancy and overlap the normal values of the test for 
PE diagnosis (Damodaram, Kaladindi, Luckit, & Yoong, 2009). However, pregnant 
women with suspected PE undergo additional testing such as a ventilation-perfusion 
(VQ) lung scan or CT with the former being conducted more frequently than the latter 
(Cahill, Stout, Macones, & Bhalla, 2009). 
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A summary of the percentages of patients for whom PE was excluded by a low or 
intermediate clinical probability or PE unlikely CDR and a negative DD by study are 
presented in Table 4. 
Table 4 
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Note. PE = pulmonary embolism; CDR = clinical decision rule; DD = D-dimer test; N = negative. 
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Clinical decision rule, D-dimer test, and computed tomography pulmonary 
angiography or invasive pulmonary angiography. 
The CT and the PA are used in PE diagnostic strategies as the only imaging tests 
following a CDR and a DD in Strategy 2 and Strategy 3. The components of Strategy 2 
include the CDR, the DD, and a CT as the only imaging test (Anderson et al., 2007; Eng, 
Wansaicheong, Goh, Earnest, & Sum, 2009; Ghanima et al., 2005; Ghaye & 
Dondelinger, 2008; Huisman & Klok, 2009; Kamphuisen & Agnelli, 2005; Nijkeuter et 
al., 2007; Perrier et al., 2005; Righini et al., 2008; Sohns, Amarteifio, Sossalla, Heuser, & 
Obenauer, 2008; Stein, Woodard, et al., 2006; van Belle et al., 2006). 
The use of single or multidetector-row CT following the evaluation of a CDR and 
a DD was strongly indicated by several researchers who suggested that there is not 
enough evidence to withhold anticoagulation treatment from a patient after only a 
negative CT without involving a CDR and/or a DD (Anderson et al., 2007; British 
Thoracic Society, 2003; Eng et al., 2009; Ghanima et al., 2005; Ghaye & Dondelinger, 
2008; Hogg, Brown, et al., 2006; Huisman & Klok, 2009; Kamphuisen & Agnelli, 2005; 
Kruip, Leclercq, Heul, Prins, & Biiller, 2003; Musset et al., 2002; Nijkeuter et al., 2007; 
Nijkeuter, Ginsberg, & Huisman, 2006; Perrier et al., 2005; Rathbun et al., 2004; Righini 
et al., 2008; Schoepf, Goldhaber, & Costello, 2004; Sohns et al., 2008; Stein, Woodard, 
et al., 2006; Trowbridge, Araoz, Gotway, Bailey, & Auerbach, 2004; van Belle et al., 
2006; Wells, 2007). 
In the Christopher study (see van Belle et al., 2006), 3,306 patients with suspected 
PE were examined. Upon examination, 2,206 patients were classified with a PE unlikely 
CDR. Of those, 1,057 obtained negative DD results and 1,149 obtained positive DD 
results. DDs were not performed for the other 1,100 patients who were classified with a 
33 
PE likely CDR. In the same study, CTs were ordered for 2,249 of the 3,306 patients: 
1,149 PE unlikely patients with positive DD results and the 1,100 PE likely patients. CTs 
were not performed for the 1,057 patients with PE unlikely CDRs and negative results for 
a DD assay. Of the 2,249 patients scheduled for either a single- or multidetector-row CT, 
PE was confirmed in 674, ruled out in 1,505, and was inconclusive for 20. Fifty of the 
scheduled CTs were not performed. The 3-month follow-up VTE rate was 1.3%> (van 
Belle et al., 2006). 
A 4-multidetector-row CT was used to diagnose 432 patients with suspected PE 
who also were evaluated in conjunction with a DD and a CDR (Ghanima et al., 2005). PE 
was ruled out in 103 patients with a negative DD and a low or intermediate clinical 
probability of PE. Among the 329 patients with a positive DD, the CT confirmed PE in 
93, ruled out PE in 221, and was inconclusive for 15. 
The combination of a CDR, a DD, and a CT was investigated in a study of 408 
patients with suspected PE (Hogg, Dawson, et al., 2006). Among the 403 patients who 
completed follow-up, PE was detected in 22 patients and excluded in 381 patients, with a 
3-month follow-up VTE rate of 0.8%. Nijkeuter and colleagues (2007) evaluated the 
combination CDR, DD, and CT in a study of inpatients and outpatients with suspected 
PE. Among the 190 patients who were indicated as having a previous PE episode, likely 
clinical probability of PE, and/or a positive DD, results from CTs excluded recurrent PE 
in 127 and confirmed recurrent PE in 63 of these patients, with a 3-month follow-up VTE 
rate of 0.8%>, indicating that this combination safely ruled out PE in patients with a 
history of PE. 
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From a population of 1,693 patients with suspected PE, Righini and colleagues 
(2008) evaluated the combination of a CDR, a DD, and a CT using a randomly selected 
sample of 815 patients. The CT confirmed PE in 160 and excluded PE in 361 of the 
sample patients with a PE low or intermediate CDR and a positive DD. The CT was 
inconclusive for 14 patients. PE was excluded in 280 sample patients who obtained a 
negative DD and a PE low or intermediate CDR. 
Results from 200 patients with suspected PE who were tested using the 
combination of a CDR, a DD, and a 64-multidetector-row CT were analyzed. Each of the 
200 patients was assessed with a high clinical probability of PE. Each achieved positive 
results from a DD. Then, each patient underwent a 64-multidetector-row CT. PE was 
confirmed in 60 patients; PE was ruled out for 140 patients. It was determined that the 
64-multidetector-row CT has an increased ability to detect conditions that mimic PE, 
including pneumonia, pneumothorax, and cardiovascular diseases. A total of 120 
incidental findings of these conditions were reported (Sohns et al., 2008). 
A follow-up of 219 cases of patients with suspected PE revealed that the 
multidetector-row CT confirmed PE in 42 patients with high clinical probability of PE 
and a positive DD. Results from this CT ruled out PE in 177 patients, including 49 who 
had a negative DD (Eng et al., 2009). 
An examination of the findings for 5,344 cases of emergency department patients 
was conducted in 2009 by Corwin and associates. They evaluated the results from the 
combination of a CDR, a DD, and a CT that used a 4- or 16-detector-row CT. PE was 
ruled out in 4,580 patients, and of those, 3,091 obtained a PE low CDR in combination 
with DD and CT tests, while 1,489 obtained a PE high CDR and a negative CT without a 
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DD test. Of the remaining 764 cases, PE was confirmed in 159 patients. Of those, 20 
obtained a PE low CDR in combination with DD and CT tests and 139 obtained a PE 
high CDR with a positive CT without a DD test. CTs were not performed in 605 patients 
who obtained a PE low CDR with positive DD and discharged for diagnoses other than 
PE (Corwin et al., 2009). 
Strategy 3 combines the testing components of a CDR, a DD, and a PA as the sole 
imaging test (Soderberg et al., 2009; van Beek et al., 2001; Winer-Muram et al., 2004). 
Using the combination of a CDR, a DD, and PA to determine PE in patients with 
suspected PE was evaluated in a study of 120 outpatients. PA confirmed PE in 34 
(28.3%) of the outpatients (Soderberg et al., 2009). Winer-Muram and colleagues (2004) 
ascertained that the combination of CDR and PA ruled out PE in 75 (80.6%) and 
confirmed PE in 18 (19.4%) of the 93 patients. Conversely, with the same patients, the 
combination of CDR and a 4-multidetector-row CT ruled out PE in 67 (72%>) and 
confirmed PE in 26 (28%) of them; the use of DD was unspecified in this study (Winer-
Muram et al., 2004). A review of eight studies conducted between 1978 and 1999 
investigating the validity of PA in patients with suspected PE revealed that the test ruled 
out PE in 1,050 patients and that the recurrence rate was 1.7% (see van Beek et al., 2001). 
The use of CDR and DD was unspecified in this review. 
Clinical decision rule, D-dimer test, computed tomography pulmonary 
angiography, and other imaging tests. 
The CT has been used in several PE diagnostic strategies as the first imaging test 
that follows a CDR and a DD. This sequence of diagnostic components is used in 
Strategies 4, 5, and 6. 
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Strategy 4 comprises the following sequence of diagnostic components: CDR, a 
DD, a CT as the first imaging test, and a CUS. In a cohort study of 858 patients with 
suspected PE, Anderson and colleagues used a CDR, a DD, a CT, and a CUS sequence to 
diagnose PE. The main results of this study follows (Anderson et al., 2005). PE was ruled 
out in 469 and confirmed in 10 patients who obtained a PE low CDR in combination with 
DD, CT, and CUS tests. PE was ruled out in 280 and confirmed in 44 patients who 
obtained a PE moderate CDR in combination with DD, CT, and CUS tests. PE was ruled 
out in 29 and confirmed in 26 patients who obtained a PE high CDR in combination with 
DD, CT and CUS tests. 
The sequence of diagnostic components that comprise Strategy 5 is the CDR, the 
DD, a CT, a CUS, and a VQ lung scan. The CT remains the first imaging test performed 
with patients with suspected PE. Perrier and colleagues (2005) evaluated Strategy 5 in a 
study of 674 patients in which 193 PE cases were detected by a CT, CUS, or VQ lung 
scan: 187 by a multidetector-row CT, 4 by a CUS, and 2 by a VQ lung scan (Perrier et 
al., 2005). 
The CT is also the first imaging test used in Strategy 6. The diagnostic 
components sequence of this strategy begins with a CDR followed by the DD, a CT, a 
CUS, and a PA. Perrier and colleagues (2005) used Strategy 6 to confirm PE in patients 
with a high clinical probability of PE. They were evaluated with a CDR and experienced 
a testing battery (DD, a multidetector-row CT, and CUS) followed by a PA. PE was 
confirmed in 82 patients by the CT and ruled out by PA for 3 patients. No VTE episodes 
occurred during the 3-month follow-up among patients for whom PE was excluded. 
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Clinical decision rule, D-dimer test, compression ultrasonography, and other 
imaging tests. 
The CUS is used in four PE diagnostic strategies as the first imaging test 
following a CDR and a DD: Strategies 7, 8, 9, and 10. In Strategy 7 (CDR, DD, CUS, 
and CT), the CUS precedes the CT. It is important to note that CUS is used to detect 
DVT, and it can indirectly detect PE in patients with suspected PE because DVT is 
present in about 30% of the patients with PE (Righini et al., 2008). 
Michiels and colleagues (2005) noted that the combination of a moderate or high 
clinical probability of PE, a positive DD, and a positive CUS detect DVT in 20 to 25% of 
patients. Michiels et al. (2005) also asserted that the use of CDR, a DD, and a CUS could 
reduce the need for CTs by 40 to 50%. The combination of CDR, a DD, and CUS was 
investigated by Elias and colleagues (2005) in a study of 274 patients with suspected PE 
(Elias et al., 2005). PE was ruled out in 165 patients and confirmed in 109 patients. CUSs 
were performed on all 274 patients: 102 were positive (i.e., PE diagnosis confirmation) 
and 64 were negative (i.e., PE excluded). The other 108 were followed by a CT, 
indicating a potential reduction of 166 (60.6%) additional imaging tests. 
In a study of 828 patients with suspected PE, Righini and colleagues (2008) 
investigated the combination of CDR, a DD, and a CUS. PE was ruled out for 660 
patients, confirmed for 150 patients, and inconclusive for 18 patients with an overall 3-
month follow-up risk of developing VTE of 0.3% (Righini et al., 2008). Of the 547 CUS 
tests performed, 38 were positive (i.e., PE diagnosis confirmation), 397 were negative 
(i.e., PE excluded), and 112 were false negative, indicating a potential reduction of 435 
(52.5%) additional imaging tests. Perrier and colleagues (1999) investigated the 
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combination of CDR, a DD, CUS, and VQ lung scans with 918 patients and found that 
CUS reduced the need for VQ lung scans in 393 (42.8%) of the patients. 
In Strategy 8 (CDR, DD, CUS, and PA), the first imaging test in the diagnostic 
tool sequence is the CUS. If necessary, then it is followed by a PA. The use of CUS was 
evaluated in an investigation of the combination of a CDR, a DD, CUS, and PA in 234 
patients with suspected PE. PE was ruled out in 182 patients and confirmed in 52 patients 
with a 3-month follow-up VTE risk for the entire strategy of 1%. Of the 174 CUSs 
performed, 27 were positive (i.e., PE confirmation) and 122 were negative (i.e., PE 
excluded), with 25 being false negatives, indicating a potential reduction of 149 (63.7%) 
additional imaging tests (Kruip et al., 2002). Reducing the need for additional imaging 
tests with the use of CUS as indicated by Strategies 7 and 8 is presented in Table 5. 
Table 5 
Percent Reduction in Use of Additional Imaging Tests Following a CUS 
Study Patient Category % Reduction in Use of Additional 
First Author & Year Imaging Tests Following CUS 
Perrier, 1999 Outpatient 42^8 
Kruip, 2002 Outpatient and Inpatient 63.7 
Elias, 2005 Outpatient 60.6 
Righini, 2008 Outpatient 52.5 
Note. CUS = compression ultrasonography. 
In Strategy 9, the CDR, DD, and CUS are followed by a CT and a PA. This 
strategy was evaluated by Perrier and colleagues (2004) in a study that included 965 
patients with suspected PE. Of those 965, 685 patients obtained positive DDs (Perrier et 
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al., 2004). Among those patients, DVT was excluded by CUS in 593 and confirmed in 
92. A subsequent CT (of the 593 patients in which DVT was excluded by CUS) excluded 
PE in 450 patients with low or intermediate clinical probability of PE, confirmed PE in 
124 patients, and was nondiagnostic in 11 patients. Among the eight patients who were 
assessed as having a high clinical probability of PE, PA excluded PE in six and 
confirmed it in two individuals. 
In Strategy 10 (CDR, DD, CUS, VQ lung scan, and PA), the first imaging test in 
the diagnostic tool sequence is a CUS, followed by a VQ lung scan and a PA, if 
necessary. Perrier and colleagues (1999) evaluated this strategy with 918 patients. A DD 
ruled out PE/DVT in 286 of the patients (Perrier et al., 1999). Of the 632 CUS performed, 
393 ruled out PE/DVT, 2 confirmed DVT, and 237 were followed by a VQ lung scan. Of 
the 237 VQ lung scans performed, 37 obtained normal-probability results (i.e., PE 
excluded), 43 obtained high-probability results (i.e., PE diagnosis confirmation), and 157 
were nondiagnostic. Of the 157 nondiagnostic VQ lung scans performed, 107 ruled out 
PE in combination with a low probability for PE, a positive DD, and a negative CUS, and 
the 50 VQ lung scans followed by a PA obtain negative results for 37 tests and positive 
results for 13 of the PAs. 
Clinical decision rule, D-dimer test, ventilation-perfusion lung scan, and 
other imaging tests. 
The ventilation-perfusion (VQ) lung scan has been used in the following PE 
diagnostic strategies as the first imaging test after a CDR and a DD: Strategies 11, 12, 13, 
and 14. In Strategy 11 (CDR, DD, VQ lung scan, and CUS), the imaging test sequence is 
a VQ lung scan followed by a CUS. Patients may repeat CUS in one week if necessary 
(Kearon et al., 2006; Perrier et al., 2000; Ten Wolde et al., 2004; Wells et al., 2001). 
The performance of this strategy was evaluated in a randomized control trial 
involving 712 patients. The use of VQ lung scans confirmed VTE in 75 patients, ruled 
out VTE in 247 patients, and produced nondiagnostic readings in 386 patients. VQ lung 
scans were not performed with four patients. The use of CUS following the nondiagnostic 
VQ lung scans among the 386 patients resulted in 15 positive CUS (i.e., VTE diagnosis 
confirmation), 360 negative CUS (i.e., VTE excluded), and 11 false negative CUS tests. 
Also, CUS was repeated in one week for 78 patients obtaining negative results from the 
first CUS test (Anderson et al., 2007). 
This strategy was also evaluated by Kearon and colleagues (2006) using two 
groups of randomly selected patients with suspected PE. Group 1 comprised 670 patients 
with a low probability of PE, a negative or positive DD, and a VQ lung scan. Group 2 
comprised 456 patients with a moderate or high clinical probability of PE and a VQ lung 
scan. The VQ lung scan in 186 Group 1 patients (low clinical probability of PE and 
negative DD) excluded PE in 97 patients and produced nondiagnostic VQ lung scans in 
86 patients. Three VQ lung scans were not performed. Among the 456 Group 2 patients 
(moderate or high clinical probability of PE, without performing a DD), 241 attained a 
nondiagnostic VQ lung scan. A CUS confirmed PE in 15 of these patients and ruled out 
PE for the remaining 226. A serial CUS was performed in 41 of the 226 patients with a 
negative DD for whom PE was excluded. Results excluded PE in 40 patients. 
Ten Wolde et al. (2004) examined this strategy through a study of 631 patients 
with suspected PE. The use of serial CUS in 224 patients with moderate or high clinical 
probability of PE, a positive DD, and a nondiagnostic VQ lung scan excluded PE in 210 
patients and confirmed PE in 14 patients. Wells et al. (2001) used a cohort study 
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composed of 930 patients with suspected PE to investigate Strategy 11. PE was excluded 
in 437 patients with a PE low probability CDR and a negative DD; 471 patients 
underwent a VQ lung scan. Among the remaining 22 patients, a DD was not performed 
with 1 patient and 21 did not receive VQ lung scans. The use of VQ lung scans among 
471 patients confirmed PE in 64 patients, ruled out PE in 183 patients, and produced 
nondiagnostic readings in 224. This study also determined that of the ordered 173 CUSs, 
which followed a nondiagnostic VQ lung scan combined or not combined with a DD, PE 
was excluded for 148 patients and confirmed for one patient. Twenty-four (24) scheduled 
CUSs were not performed. Perrier and colleagues (2000) assessed this strategy using the 
results from 837 patients with suspected PE. Of the 180 patients with a low clinical 
probability of PE and an inconclusive VQ lung scan, a follow-up CUS excluded PE in 
175 (20.9%) and confirmed DVT in 5 (0.6%) of these patients. A 3-month follow-up 
revealed a VTE rate of 1.7%. The probability levels for diagnosing PE with VQ lung 
scans after a CDR and DD is presented in Table 6. 
Table 6 
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Note. PE = pulmonary embolism; VQ = ventilation-perfusion lung scan; CDR = clinical decision rule. 
42 
In Strategy 12 (CDR, DD, VQ lung scan, CUS, and CT), the VQ lung scan is the 
first imaging test performed in this diagnostic tool sequence. If necessary, it is followed 
by a CUS, then a CT. In a randomized control trial, Anderson et al. (2007) evaluated the 
performance of Strategy 12 with 712 patients. The use of CT following a nondiagnostic 
VQ lung scan and a positive CUS, confirmed PE in 6 additional patients and ruled out PE 
in 17 patients. 
In Strategy 13 (CDR, DD, VQ lung scan, CUS, and PA), the VQ lung scan is the 
first imaging test performed in this diagnostic tool sequence. It is followed by a CUS, 
then a PA, if necessary (Perrier et al., 1996; Quinn et al., 1994). In the Anderson and 
colleagues (2007) study cited with strategy 12, a PA following the VQ lung scan-CUS 
sequence and performed independently of the CT tests confirmed PE in 3 patients and 
ruled out PE in 3 additional patients. Perrier and colleagues (1996) investigated this 
strategy in 308 patients with suspected PE. VQ lung scan ruled out PE in 43 patients, 
confirmed PE in 63 patients, and was nondiagnostic in 202 patients. The use of CUS 
indicated no DVT in 77 patients and confirmed DVT in 22 patients with a nondiagnostic 
VQ lung scan, a PE moderate CDR, and a positive DD. Among these 77 patients, testing 
with a follow-up PA ruled out PE in 55 patients and confirmed PE in 22. The 6-month 
follow-up VTE risk rate for the entire strategy was 1%. 
An investigation of 36 patients with suspected PE indicated intermediate-
probability VQ lung scan results for PE in all 36 patients. PE was confirmed by a follow-
up CUS in 7 patients and by a follow-up PA in 15 patients (Quinn et al., 1994). 
As in the previous three strategies, Strategy 14 (CDR, DD, VQ lung scan, and CT 
or PA) incorporates a VQ lung scan as the first imaging test conducted on patients with 
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suspected PE. It is followed by a CT or a PA. This strategy was suggested by Bajc and 
colleagues (2009b) in the guidelines of the European Association of Nuclear Medicine. 
Review of PE Diagnostic Strategy CEA Studies 
CEA studies published in the 1990s and 2000s. 
In an early application of a cost-effectiveness analysis (CEA) for PE diagnostic 
strategies Oudkerk, van Beek, van Putten, and Biiller (1993) classified nine diagnostic 
strategies that did not employ clinical decision rules (CDR) or D-dimer tests (DD) into 
three categories (CEA 1). Oudkerk and colleagues concluded that the most cost-effective 
strategy should include PA and that the use of VQ lung scan and CUS can reduce the 
need for PA from 40 to 50%. 
Hull, Feldstein, Stein, and Pineo (1996) also evaluated three diagnostic strategies 
that did not include a CDR or DD (CEA 2). The first strategy included VQ lung scan and 
PA; the second strategy included VQ lung scan, CUS, and PA; the third strategy 
employed a VQ lung scan, serial CUS, and PA. The average cost per patient by strategy 
was assessed at $14,421, $14,407, and $13,842, respectively. Hull et al. concluded that 
the combination of a VQ lung scan, serial CUS, and PA was the most cost-effective 
method of diagnosing a pulmonary embolism. 
In their examination of diagnostic strategies using a VQ lung scan, a CDR, a DD, 
a PA, and a CUS, Michel, Seerden, Rutten, van Beek, and Biiller (1996) analyzed 
assigned CDR cut-off points and DD cut-off values (CEA 3). They identified a PE 
diagnosis cost-per-patient for 12 strategies between $4,118 and $4,339 with 6-month 
survival rates between 91.05% and 97.42%. The strategy that emerged as the most cost-
effective commenced with a VQ lung scan followed by a CDR with an assigned cut-off 
value of 0.075, a DD with an assigned cut-off value of 300, a PA, and a CUS. 
Twelve PE diagnostic strategies evaluated by van Erkel, van Rossum, Bloem, 
Kievit, and Pattynama (1996) comprised a single or a combination of as many as five PE 
diagnostic tools. Four (4) of the 12 diagnostic strategies employed the PA as the final 
test, and 8 incorporated CT as the final test (CEA 4). The researchers determined that the 
strategy that combined a CUS with a subsequent CT was the most cost effective with a 
cost of $20,562 per life saved. This evaluation demonstrated that the use of CT in PE 
diagnostic strategies could reduce mortality rates and achieve more cost-effective results. 
Perrier and associates investigated six PE diagnostic strategies that included 
combinations of VQ lung scan, DD, CUS, and/or PA (CEA 5) (Perrier et al., 1997). Each 
of the six strategies included a VQ scan, and five strategies employed PA as the final test. 
The research concluded that strategies with a DD and a CUS preceding or following a 
VQ lung scan are cost effective given that they resulted in a 37 to 47% decrease in the 
need for PA tests. 
A CEA conducted by Larcos, Chi, Shiell, and Berry (2000) investigated three PE 
diagnostic strategies. The first employed a CT only. The second included a CT with CUS 
and PA. The third was composed of a VQ lung scan, CUS, and PA (CEA 6). The third 
diagnostic strategy was assessed as the most cost-effective with a cost of $940 per life 
saved. 
Hull et al. (2001) also examined three PE diagnostic strategies with data 
extrapolated from the Prospective Investigation of Pulmonary Embolism (PIOPED I) 
study of 662 patients with suspected PE (CEA 7). All three strategies included the VQ 
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lung scan as the first test. The first strategy combined the VQ lung scan and a subsequent 
PA. The second strategy combined the VQ lung scan with a subsequent CUS and PA. 
The third strategy combined the VQ lung scan with subsequent serial CUS and PA. The 
cost per patient for the first, second, and third strategies was $10,761, $10,364, and 
$8,915 (Canadian dollars), respectively. This study revealed that the third strategy is the 
most cost-effective method of PE diagnosis among patients with suspected PE. 
Combinations of VQ lung scan, CUS, CT, and PA were included in a CEA of PE 
diagnostic strategies conducted by Paterson and Schwartzman (2001). They investigated 
seven different strategies (CEA 8), three of which involved the PA as the final test. Three 
other strategies employed the CT as the final procedure, and one strategy used the CUS 
as the last test performed. This analysis revealed two of the seven strategies examined as 
cost-effective. The more cost-effective strategy of the two identified as such combined a 
VQ lung scan, a CUS, and the CT that produced a survival rate of 953.4 per 1,000 
patients at a cost-per-patient of $1,391 (Canadian dollars). 
Perrier and Bounameaux (2001) reviewed the performance of several diagnostic 
strategies in patients with suspected PE (CEA 9). The first strategy combined the CDR 
and DD with a subsequent CUS, VQ lung scan, and PA. The five strategies resulted in a 
savings per additional QALY (quality-adjusted life year) of $2,467, $2,447, $2,700, 
$3,202, and $3,439, respectively. Overall, this study revealed that the first strategy was 
the most cost-effective with 38 lives saved per 1,000 patients and a savings per additional 
QALY of $2,467. 
Low, intermediate, or high clinical probability of PE patient classifications as well 
as CT in eight PE diagnostic strategies was the basis for a CEA conducted by Perrier et 
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al. (2003) (CEA 10). For patients with a low clinical probability of PE, the most cost-
effective strategy employed the DD, CUS, and VQ lung scan at a cost of $845 per 
patient. For patients with an intermediate clinical probability of PE, this analysis 
demonstrated that the most cost-effective strategy included a DD, CUS, VQ lung scan, 
and CT at a cost of $2,674 per patient. For those in the high clinical probability of PE 
group, the strategy that included a DD, CUS, and PA was the most cost-effective at a cost 
of $4,598 per patient because it required a subsequent PA in 25% of the cases. 
An evaluation of the cost effectiveness of three PE diagnostic strategies in 
pregnant women with suspected PE was conducted by Doyle and colleagues (2004) 
(CEA 11). The first strategy commenced with a CUS followed by a VQ lung scan, a CT, 
or a PA. The second strategy used a VQ lung scan as the primary test in a combination of 
diagnostic tools, and the third strategy employed the CT as the first procedure in a 
combination with other diagnostic tools. Doyle et al. revealed that the CT scan as the 
primary test (i.e., third strategy) resulted in the most cost-effective diagnostic strategy 
with a cost of $ 17,208 per life saved compared to a cost of $24,004 per life saved for the 
first strategy and a cost of $35,906 per life saved for the second strategy. 
The cost-effectiveness of CUS as a diagnostic tool for determining PE was 
investigated (Elias, Molinier, et al., 2004) in a CEA, which includes nine separate 
diagnostic strategies (CEA 12) that comprised various combinations of CDR, DD, CUS, 
CT, VQ lung scan, and PA. Three strategies emerged as cost effective. One such strategy 
included a DD, extensive CUS, and CT with a cost of $3,679 per patient and a survival 
rate of 95.11%. A second cost-effective strategy included a DD, CUS, and CT with a cost 
of $3,719 and a survival rate of 95.53%). The third diagnostic strategy that emerged as 
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cost effective included a CUS and CT with a cost of $3,804 per patient and a survival rate 
of 95.89%o. Of these three, the most cost-effective strategy was that which included the 
CUS and CT with an ICER of $23,649 per additional life saved. 
Ten imaging strategies for diagnosing PE were investigated by Duriseti, Shachter, 
and Brandeau (2006) by examining the assigned values of five different cut-off points for 
DD and the level of clinical probability of PE (CEA 13). The researchers concluded that 
the DD with CUS as the pulmonary imaging test has utility, but when a CT is available, 
the DD does not result in a cost-effective strategy. 
The influence of age was evaluated by Righini, Nendaz, Le Gal, Bounameaux, 
and Perrier (2007) in a study of four strategies used to diagnose patients with suspected 
PE (CEA 14). One diagnostic strategy commenced with a CDR and DD followed by 
CUS and CT. Another commenced with a CDR and DD in combination with only a 
subsequent CT. The strategy employing a CUS was more expensive than strategies not 
using a CUS. The strategy that included a CDR, a DD, and CT was the most economical 
with a 3-month VTE risk of less than 1%. 
Costs. 
The expense of diagnosing PE involves several costs, including laboratory and 
imaging tests as well as those associated with treating patients, which, in addition to 
prescribed treatment, may include treatment for any complications and hospital stays. 
Each is a very significant element in a CEA and represents the direct costs related to PE 
screening under a third-party payer perspective. 
However, none of the CEAs published in the 1990s as well as in the past decade 
calculated indirect costs such as productivity loses in PE patients due to hospitalization or 
the costs of long-term effects of PE in patients (see Cox, Carson, & Biddle, 2003; Doyle 
et al., 2004; Elias, Molinier, et al., 2004; Hull et al., 1996; Hull et al., 2001; Larcos et al., 
2000; Michel et al., 1996; Paterson & Schwartzman, 2001; Perrier et al., 1997; Perrier et 
al., 2003; Righini et al., 2007; van Erkel et al., 1996). 
In the 1990s, direct costs associated with diagnostic tests, patient treatment, and 
patient hospitalization were assessed by Hull and colleagues (1996), Michel and 
colleagues (1996), Perrier and colleagues (1997), and van Erkel and colleagues (1996). 
Hull and colleagues used the average costs of $510 for a VQ lung scan, $300 for CUS, 
$1,500 for serial CUS, and $2,553 for PA in their CEA. The average cost-per-patient of 
treatment of $6,522 was classified as costs related to anticoagulant treatment, including 
the medications, laboratory tests performed to monitor anticoagulant treatment, and 
physicians' fees, as well as costs of complications and side effects. The average 
hospitalization cost was $575 per day and included the hospital stay, laundry charges, and 
meals (Hull et al., 1996). In their systematic examination of extrapolated data retrieved 
from published studies, van Erkel and colleagues determined that the most expensive 
imaging test was the PA with an associated cost of $660 (van Erkel et al., 1996). Direct 
costs also were studied by Michel and colleagues (1996). These costs included medical 
expenses such as hospital stays, diagnostic tests, and treatment. Indirect costs such as 
productivity losses were not calculated. It was determined that the most expensive test 
was the PA with an associated cost of $765 (Michel et al., 1996). Only direct costs were 
estimated in the Perrier et al. (1997) CEA, which included costs for diagnostic tests, 
treatments, and major complications. The average costs of a VQ lung scan and PA were 
calculated at $301 and $1,038, respectively. 
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As in the previous decade, CEA studies published in first decade of the 21st 
century used only direct costs in their analyses (see Cox et al., 2003; Doyle et al., 2004; 
Elias, Molinier, et al., 2004; Hull et al., 2001; Larcos et al., 2000; Paterson & 
Schwartzman, 2001; Perrier et al., 2003; Righini et al., 2007). A study conducted in 
Australia calculated average costs for hospital stays and treatment derived from the 
country's Medicare benefits schedule for diagnostic tests and from groups monitoring 
hospital admissions. The average hospitalization cost for a PE patient per day was $325, 
and the average cost for PE treatment per day was $1,977 (Larcos et al., 2000). 
The CEA by Hull and colleagues (2001) considered the costs of the diagnostic 
tests performed as well as the costs of the treatment, including therapy, hospitalization, 
and medical side effects. Specifically, therapy costs included the price of drugs, 
laboratory tests used to monitor treatment, and corresponding physicians' fees. 
Hospitalization costs were composed of room and laundry charges with an average cost-
per-patient of $604 (Canadian dollars) per day. The costs of side effects, which averaged 
$4,644 (Canadian dollars) per patient per day, were those associated with medical side 
effects and complications from the anticoagulant therapy (Hull et al., 2001). In their 
CEA, Paterson and Schwartzman (2001) determined average direct costs derived from 
Canadian financial services monitoring hospital costs and physicians' fees. Expenditures 
for PE diagnostic tests included technical, professional, and capital costs. An average cost 
for a PE hospital stay was calculated using several categories of costs, including 
diagnostic tests, physician and nursing fees, prescription drugs, and hospital bed/room 
with an average hospitalization cost of $7,798 (U.S. dollars). 
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Direct costs were retrieved from a hospital database by Perrier et al. (2003) for 
their CEA; they did not calculate indirect costs. An overall average cost for PE treatment 
of $5,982 per patient was reported. This amount included costs for diagnostic tests, 
hospital stays, treatment and monitoring, and those related to major bleeding episodes. 
The D-dimer test was the most economical ($33), and the PA was the most expensive 
($1,038). 
Direct costs retrieved from the literature were used in a CEA that indicated an 
average cost of $7,839 per PE episode, ranging from $5,252 to $10,426 inclusive, as well 
as an average cost of $807 per day for hospitalization, ranging from $505 to $1,009 (Cox 
et al., 2003). Direct costs retrieved from previous CEA studies were used by Doyle and 
colleagues (2004) to determine average costs for diagnostic tests and treatment. An 
average cost of $200 was assigned to CUS and an average cost of $5,982 per patient was 
assigned for treatment (Doyle et al., 2004). Direct costs also were examined in the 
Righini and colleagues (2007) CEA; indirect costs were not. An average cost of $184 was 
assigned to CUS, and an average cost of $5,982 was assigned for treatment (Righini et 
al., 2007). 
In any presentation of costs associated with PE diagnostic tools, costs of tests and 
treatment may differ widely among countries and even among hospitals within a 
particular country. These differences may seriously affect the accuracy of a CEA to 
determine the most cost-effective PE diagnostic strategy. Most CEAs investigating the 
diagnosis and treatment of PE were conducted in North America (i.e., USA and Canada) 
and in northern European countries (e.g., the Netherlands and Switzerland) (see Cox et 
al., 2003; Doyle et al., 2004; Elias, Molinier, et al., 2004; Hull et al., 1996; Hull et al., 
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2001; Larcos et al., 2000; Michel et al., 1996; Paterson & Schwartzman, 2001; Perrier et 
al., 1997; Perrier et al., 2003; Righini et al., 2007; van Erkel et al., 1996). A study of 
costs among six countries, Austria, France, Great Britain, Switzerland, The Netherlands, 
and the United States (van Erkel, van Den Hout, & Pattynama, 1999), revealed that the 
most economical diagnostic test for PE detection is the D-dimer test. The average cost of 
its administration was cited as $19 U.S. dollars. The study also revealed that the most 
expensive diagnostic test is the PA; its average cost was cited as $432, ranging from $190 
in France to $797 in the Netherlands. The average cost of treating PE ranges widely 
among the six countries with a low of $1,385 in Great Britain and a high of $21,182 in 
the United States (van Erkel et al., 1999). 
Effectiveness. 
Defining and measuring effectiveness are essential components of a CEA. How 
effectiveness is defined varies among CEAs published in the 1990s and 2000s (see Cox et 
al., 2003; Doyle et al., 2004; Elias, Molinier, et al., 2004; Hull et al., 1996; Hull et al., 
2001; Larcos et al., 2000; Michel et al., 1996; Paterson & Schwartzman, 2001; Perrier et 
al., 1997; Perrier et al., 2003; Righini et al., 2007; van Erkel et al., 1996). CEA studies 
published in the 1990s measured effectiveness by (a) establishing criteria for the correct 
(accurate) detection of PE and the correct (appropriate) withholding of treatment or (b) 
the 3-month mortality and morbidity rates as well as the 6-month survival rate (Hull et 
al., 1996; Michel et al., 1996; Perrier et al., 1997; van Erkel et al., 1996). To measure 
effectiveness, Hull and colleagues established two criteria: (a) the accuracy of PE 
detection in conjunction with the costs associated with a correctly treated patient and (b) 
the number of patients with suspected PE for whom treatment was accurately withheld in 
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conjunction with the costs associated with establishing that these patients did not require 
any treatment (i.e., diagnostic strategy implemented) (Hull et al., 1996). Three-month 
mortality and morbidity rates were used to measure effectiveness in the van Erkel CEA. 
The marginal effectiveness of a diagnostic strategy was calculated based upon the costs 
associated with each additional life saved. The diagnostic strategy with the lowest 
marginal effectiveness was the most cost-effective (van Erkel et al., 1996). Effectiveness 
was estimated using 6-month survival rates, mortality rates retrieved from CEA data, and 
mortality rates subsequent to a PA retrieved from the literature by Michel et al. (1996). In 
the Perrier and colleagues (1997) CEA, effectiveness was measured using parameters that 
included mortality rates of treated PE, untreated PE, and treatment subsequent to PA 
results (Perrier et al., 1997). 
CEA studies published during the first decade of the 21st century measure 
effectiveness using several methodologies. The ratio of average costs per life-year was 
used by the Larcos and colleagues (2000) CEA in which the total cost of each diagnostic 
strategy was calculated and then divided by the life-years experienced in each group of 
patients (Larcos et al., 2000). The Hull and colleagues (2001) CEA applied the two 
criteria used in Hull et al. (1996): the accurate detection of VTE followed by the accurate 
identification of patients in which treatment was withheld. This study identified 194, 195, 
and 169 patients who correctly received treatment, and 468, 467, and 493 patients who 
were correctly left untreated based upon the first, second, and the third evaluated 
strategies, respectively (Hull et al., 1996). Paterson and Schwartzman (2001) measured 
effectiveness with a 3-month survival rate following an initial PE episode, 3-month 
mortality rates for untreated PE (31%), and for treated PE (6.5%>) from both older and 
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more recent studies of PE diagnostic strategies they examined. Effectiveness was 
measured in a CEA using the 3-month quality-adjusted expected survival rate (Perrier et 
al., 2003). In this study, calculations of the 3-month survival rate involved parameters, 
such as treated PE or untreated PE, mortality rate of treated PE (based upon older 
studies), and anticoagulant therapy. In the Doyle and colleagues (2004) CEA, 
effectiveness was measured by mortality rates for untreated and treated PE retrieved from 
previous CEA studies. Effectiveness in the Elias, Molinier, et al. (2004) CEA was 
measured by the 3-month survival rates from the literature that were based upon mortality 
rates associated with a CT, PA, and PE treatment (see Barritt & Jordan, 1960; Carson et 
al., 1992; Dalen & Alpert, 1975; Douketis, Kearon, Bates, Duku, & Ginsberg, 1998; 
Elias, Molinier, et al., 2004; Giuntini, Di Ricco, Marini, Melillo, & Palla, 1995; Levine, 
Raskob, Beyth, Kearon, & Schulman, 2004; Perrier et al., 2003; Stein et al., 1992). 
Righini and colleagues (2007) used the 3-month quality adjusted expected survival rate as 
it was described in the Perrier CEA (Perrier et al., 2003) to measure effectiveness. 
Righini et al. used mortality rates for CT, PA, and treatment protocols retrieved from the 
literature. Concerns were expressed by Rosen (1999) that the mortality rate for untreated 
PE of 25%) used in the van Erkel CEA was very high (see Barritt & Jordan, 1960; Dalen 
& Alpert, 1975; Rosen, 1999; van Erkel et al., 1996). This mortality rate continued to be 
used in later CEA studies (see Elias, Molinier, et al., 2004; Perrier et al., 2003). Concerns 
also were expressed by Lipchik et al. (2004) regarding the lack of CT venography 
inclusion in the 2003 Perrier CEA. Additional concerns were expressed by Sodhi and 




Pulmonary embolism diagnosis continues to challenge physicians who must select 
a diagnostic strategy from a variety of adequate diagnostic tools that includes CDRs, D-
dimer tests, and imaging tests. Clinical decision rules (CDRs) can exclude PE in 10% of 
the patients and can assign a high clinical probability of PE in 14 to 23%> of patients with 
suspected PE. Both the exclusion of PE in some patients and the assignment of a high 
clinical probability of PE in others contributes to the reduction of diagnostic costs by 
eliminating the need for further diagnostic procedures (Chagnon et al., 2002;Gibson, 
Sonne, Kruip, et al., 2008; Klok et al., 2008; Laupacis, Sekar, & Stiell, 1997; Le Gal, 
Righini, Roy, et al., 2006; Miniati et al., 2003; Shapiro, 2006; Stein, 2007b; Wells et al., 
2000; Wicki et al., 2001). D-dimer tests (DD) are blood tests with a sensitivity ranging 
from 82 to 100%>, but a specificity ranging from 36 to 58%, which allows physicians to 
rule out PE in a significant proportion of the patients with negative DD, thereby reducing 
the need for additional costly diagnostic imaging tests (see Bruinstroop et al., 2009; De 
Moerloose et al., 2008; Di Nisio et al., 2007; Ghanima & Sandset, 2007; Hogg et al., 
2005; Kline et al., 2006; Parent et al., 2007; Stein, 2007a; Than et al., 2009; Toulon et al., 
2009; van Belle et al., 2006). Normal- and high-probability VQ lung scans have excellent 
sensitivity and specificity for PE diagnosis. The use of VQ lung scans can reduce the cost 
of PE diagnosis by eliminating the need for further imaging tests; unfortunately, most (50 
to 70%>) of these scans are nondiagnostic and necessitate further diagnostic procedures 
(see Bajc & Jonson, 2009; Bajc et al., 2009a; Bajc et al., 2004; Cook & Kyriou, 2005; De 
Geeter et al., 2005; Douma, Kamphuisen, et al., 2009; Einstein et al., 2007; Freeman & 
Haramati, 2009; Freeman et al., 2008; Gutte et al., 2010; Gutte et al., 2009; Hull et al., 
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1990; Itti et al., 2002; Meignan, 2002; Parker et al., 2005; Perrier, 2007; Reinartz et al., 
2004; Roach et al., 2008; Scarsbrook et al., 2007; Sostman, Miniati, et al., 2008; 
Sostman, Stein, et al., 2008; Stein et al., 2009; Stein, Kayali, et al., 2004b; Stein, 
Woodard, et al., 2006; Uren, 2009; Zophel, et al., 2009). Compression ultrasonography 
(CUS) of the lower limb veins is a noninvasive test that can be performed in a hospital's 
intensive care unit and detects PE indirectly by diagnosing DVT. However, only about 
30% of the patients with confirmed PE have DVT detected by compression 
ultrasonography (see Elias et al., 2005; Elias, Colombier, et al., 2004; Galle et al., 2001; 
Kalva et al., 2008; Kearon & Ginsberg, 1998; Le Gal, Righini, Sanchez, et al., 2006; 
Michiels et al., 2005; Paterson & Schwartzman, 2001; Perrier, 2007; Perrier et al., 2003; 
Perrier et al., 2004; Quiroz et al., 2005; Righini et al., 2009; Righini et al., 2008; Turkstra 
et al., 1997). Computed tomography pulmonary angiography (CT) is a noninvasive, quick 
test that has been the first-line imaging test for PE detection during the past 10 years. A 
negative CT can exclude PE in about 98%> of patients with suspected PE, while 
approximately 3% of CT scans are nondiagnostic (see Brenner & Hall, 2007; De Monaco 
et al., 2008; Ghaye & Dondelinger, 2008; Goodman & Lipchik, 1996; Goodman & van 
Beek, 2009; Kalva et al., 2008; Mos et al., 2009; Perrier et al., 2005; PIOPED 
Investigators, 1990; Quiroz et al., 2005; Remy-Jardin et al., 1996; Remy-Jardin et al., 
1992; Revel et al., 2005; Schoepf & Costello, 2005; Stein, Fowler, et al., 2006; Stein, 
Kayali, et al., 2004b; Stone et al., 2003; Turkstra et al., 1997; van Belle et al., 2006; Van 
Rossum et al., 1996; Vigo et al., 2006; Wang et al., 2009). Invasive pulmonary 
angiography (PA) was the gold standard procedure of PE diagnosis for many decades, but 
despite its excellent accuracy with a very high sensitivity of 96% and a very high 
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specificity of 97%, physicians resort to it as the last procedure because it is invasive, not 
available in all hospitals, and expensive (see Brenner & Hall, 2007; De Monaco et al., 
2008; Ghaye & Dondelinger, 2008; Goodman & Lipchik, 1996; Goodman & van Beek, 
2009; Kalva et al., 2008; Mos et al., 2009; Perrier et al., 2005; PIOPED Investigators, 
1990; Quiroz et al., 2005; Remy-Jardin et al., 1996; Remy-Jardin et al., 1992; Revel et 
al., 2005; Schoepf & Costello, 2005; Stein, Fowler, et al., 2006; Stein, Kayali, et al., 
2004b; Stone et al., 2003; Turkstra et al., 1997; van Belle et al., 2006; Van Rossum et al., 
1996; Vigo et al., 2006; Wang et al., 2009). 
Diagnostic tools such as the D-dimer tests and the multidetector-row CT, continue 
to improve as research innovations are tested. However, Balas and Boren (2000) noted 
that clinical research findings enter daily practice after about 17 years, which represents a 
considerable lag between research and practice, which affects all aspects of diagnosis, 
including costs and effectiveness. 
Combinations of certain diagnostic criteria that match the level of clinical 
probability of PE and the findings of DD and imaging tests can safely rule out or confirm 
PE in patients with suspected PE. Studies have demonstrated that the combination of low 
clinical probability of PE and a negative D-dimer test can safely rule out PE without 
further imaging tests in 24 to 47% of the patients with suspected PE. Also, certain studies 
have revealed that PE can be detected in a significant segment of patients with suspected 
PE by using a simple diagnostic tool combination of a CDR, a DD, and CT or PA (see 
Anderson et al., 2007; Eng et al., 2009; Ghanima et al., 2005; Ghaye & Dondelinger, 
2008; Huisman & Klok, 2009; Kamphuisen & Agnelli, 2005; Nijkeuter et al., 2007; 
Perrier et al., 2005; Righini et al., 2008; Sohns et al., 2008; Stein, Woodard, et al., 2006; 
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van Belle et al., 2006). Findings from other studies have indicated that PE can be detected 
in a large portion of patients with suspected PE by using more complex diagnostic 
strategies of CDR and DD with various combinations of CT, CUS, VQ lung scan, and PA 
(see Anderson et al., 2007; Anderson et al., 2005; Elias et al., 2005; Hammond & Hassan, 
2005; Kearon et al., 2006; Kruip et al., 2002; Perrier et al., 2004; Perrier et al., 2005; 
Righini et al., 2008; Wells et al., 2001). As Table 7 demonstrates, triangular distributions, 
y distributions, and Monte Carlo Simulation analysis were not applied in previous CEA 
studies. A list of studies summarizing the CEA methodology of PE diagnostic strategies 
is presented in Table 7. 
Table 7 
Summary of CEA Methodology of PE Diagnostic Strategies 
Study Decision Tree Triangular and y Deterministic 
First Author & Year Model Distributions Applied Sensitivity 


























Note. PE = pulmonary embolism; CEA = cost-effectiveness analysis. 
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Gap in the Literature 
The literature review demonstrated that a substantial amount of research 
examined PE clinical decision rules (CDR); evaluated PE diagnostic tests such as the D-
dimer test (DD), the computed tomography pulmonary angiography (CT), the 
compression ultrasonography (CUS), the ventilation-perfusion (VQ) lung scan, and the 
invasive pulmonary angiography (PA); and appraised the performance of PE diagnostic 
strategies to detect PE in patients with suspected PE. The literature also suggested that a 
cost-effectiveness analysis (CEA) might be a valuable technique for assessing the 
performance of these strategies; however, as Table 7 indicates, there is a dearth of 
research regarding CEA of PE diagnostic strategies. No research was discovered 
regarding a CEA in conjunction with triangular distributions, y distributions, and Monte 
Carlo Simulation as a methodology for evaluating the performance of PE diagnostic 
strategies. Hence, there exists a need for a CEA that applies the triangular and y 
distributions as well as the Monte Carlo Simulation as a method by which the cost-
effectiveness of PE diagnostic strategies can be assessed when examining PE detection 
failure rates. Such an approach may prove to be a valuable addition to the literature 






The purpose of this study was to assess the most cost-effective diagnostic strategy 
among several strategies currently in use for patients with suspected PE based upon their 
screening failure rates. Diagnostic strategy selection directly influences the cost and 
effectiveness of a PE diagnosis. The identification of cost-effective strategies and/or the 
most cost-effective strategy is significant to the medical decision making process (PE 
early diagnosis) and for the delivery of health services (PE treatment). Such discovery 
can result in a broader use of a particular strategy or strategies that are less expensive and 
more effective than alternate strategies (Cox et al., 2003; Doyle et al., 2004; Elias, 
Molinier, et al., 2004; Hull et al., 1996; Hull et al., 2001; Larcos et al, 2000; Michel et al., 
1996; Paterson & Schwartzman, 2001; Perrier et al., 1997; Perrier et al., 2003; Righini et 
al., 2007; van Erkel et al., 1996). 
Human Subjects Review 
Secondary aggregated data were used for this study and retrieved from published 
studies in the literature. Thus, there was no need to obtain consent from the subjects who 
participated in the original studies analysed for this research. Therefore, an approval for 
exemption was obtained from Old Dominion University's College of Health Sciences 
Human Subjects Review Committee. 
Target Population 
The population of this study was patients with suspected PE who were either 
outpatients in hospital emergency departments or inpatients following a hospital 
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admission. The study population consisted of patients with suspected PE who participated 
in studies published from January 2000 to December 2010, as either an outpatient or 
inpatient, of all adult age groups, without restrictions to race or gender or socioeconomic 
status. 
Definitions of Input Variables 
PE diagnostic strategy tests and treatment, the three constructs of the decision tree 
model, the statistical methods that comprise this research, the measurement tools applied, 
and the variables tested were identified, operationally defined, and described from the 
literature (see Beyer & Scellong, 2007; Brenner & Hall, 2007; De Milto & Odle, 2006; 
Dutton et al., 2009; Fenwick, 2009b; Ford-Martin, 2006; Jekel et al., 2001; Klok et al., 
2008; Lapin & Whisler, 2002; Mazur, 2009; Miller, 2009; Muennig, 2008; Odle, 2006; 
Petitti, 2000; Sonnenberg, 2009; van Loveren et al., 2009; Wells, 2007a, 2007b). PE 
diagnosis consisted of the following terms: strategy, treatment, CDR, D-dimer test, CT, 
VQ lung scan, CUS, and PA. The decision tree model constructs were act, event, and 
outcome. The analytical methods that comprise the design of the study include parameter 
estimation, a decision tree model applied to a cost-effectiveness analysis (CEA), Monte 
Carlo Simulation as well as one-way, two way, and three-way sensitivity analyses. 
Measurement terms included prior probability, posterior probability, dominant strategy, 
and dominated strategy. The variables that were examined were the direct costs and 
effectiveness of PE diagnosis and treatment as well as the incremental cost-effectiveness 
ratio. Each of these terms is defined in Table 8. 
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Table 8 





Decision, Diagnostic, and 
Measuring Tools 
Act Act 
Action chosen by the decision maker PE diagnostic strategies 
(Lapin & Whisler, 2002) representing initial actions 
Clinical decision rule (CDR) CDR 
Decision tool based upon clinical Scoring system measuring the 
variables assessing the probability of pretest probability of PE based 
a disease diagnosis in a patient (Klok upon clinical variables 
et al., 2008) 
Compression ultrasonography 
(CUS) 
Three CUS techniques: "(a) 
segmental CUS, examining the 
common femoral vein and the 
popliteal vein; (b) extended CUS, 
examining the complete deep thigh 
veins and popliteal vein; (c) complete 
CUS, of all segments of the deep 
thigh and calf veins (Beyer & 
Scellong, 2007) 
CUS 
Imaging test to detect DVT 
and an essential test to 
indirectly detect PE using the 
two-point compression 
ultrasound (2-CUS), the 
extended compression 




All actions on the left side of 
the decision tree structure 
(Lapin & Whisler, 2002) 
CDR 
Pretest probability of PE is 
expressed in numbers in two 
categories (PE unlikely or PE 
likely) or in three categories 
(low, intermediate or high) 
CUS 
Results are read as negative, 
positive, or nondiagnostic for 
PE 






Decision, Diagnostic, and 
Measuring Tools 
Computed tomography pulmonary 
angiography (CT) 
Combination of X-ray and computer 
images providing cross-sectional 
views of patient organs and tissues 
(Brenner & Hall, 2007; Odle, 2006) 
Cost-effectiveness analysis (CEA) 
Method of comparing two or more 
strategies in terms of their costs and 
effectiveness (Muennig, 2008) 
D-dimer test (DD) 
By-product of the breakdown of 
fibrin found in blood clots (Wells, 
2007a) 
Decision tree model (DTM) 
A decision-making model combining 
three constructs, 
action, event, and outcome 
(Lapin & Whisler, 2002) 
CT 
Fast, noninvasive PE 
diagnostic test able to directly 
image a clot as the X-ray 
source and detectors rotate, 
producing a spiral or helical 
scan 
CEA 
Comparison of cost and 
effectiveness of a PE strategy 
with other available 
alternative PE strategies 
DD 
Blood tests that allow 
physicians to rule out PE in 
patients with suspected PE 
DTM 
The action construct includes 
PE diagnostic strategies. The 
event construct includes 
CDRs, diagnostic tests, and 
probabilities. The outcome 
construct includes any payoff. 
CT 
Results are read as negative, 
positive, or nondiagnostic for 
PE 
CEA 
Assessing the value of each 
PE diagnostic strategy under 
specific units of cost and 
effectiveness 
DD 
Results are read as negative, 
positive, or nondiagnostic for 
PE 
DTM 
Triangular and y distributions 
of costs and effectiveness as 
well as event probabilities 






Decision, Diagnostic, and 
Measuring Tools 
Direct costs 
The use of services and goods 
(Petitti, 2000) 
Diagnostic strategy 
Diagnostic procedure based upon 
combinations of clinical decision 
rules, diagnostic laboratory tests, and 
imaging tests 
Dominant strategy 
Strategy that demonstrates greater 
effectiveness and lower cost than one 
competing strategy (Miller, 2009) 
Dominated strategy 
Strategy that demonstrates less 
effectiveness and higher cost than 
one competing strategy (Miller, 
2009) 
Effectiveness 
Measure of an intervention's 
performance (Muenning, 2008) 
Direct costs 
PE diagnostic tests costs, PE 
treatment costs, and PE 
hospitalization costs 
Diagnostic strategy 
Combinations of PE clinical 
decision rules, D-dimer tests, 
and PE imaging tests to detect 
PE 
Dominant strategy 
Strategy considered the 
dominant strategy if it is more 
effective and less expensive 
compared to an alternative 
strategy 
Dominated strategy 
Strategy dominated if it is less 
effective and more expensive 
than an alternative strategy 
Effectiveness 
Performance of an entire PE 
diagnostic strategy 
Direct costs 
Laboratory and imaging tests 
costs, treatment costs, and 
hospitalization costs 
Diagnostic strategy 
PE diagnostic strategy 
composition 
Dominant strategy 
Effectiveness and cost units 
Dominated strategy 
Effectiveness and cost units 
Effectiveness 
Includes the failure rate to 
Detect PE after implementing 
a strategy 






Decision, Diagnostic, and 
Measuring Tools 
Event 
Component of the decision under 
uncertainty that follows an initial 
action (Lapin & Whisler, 2002) 
Event 
PE diagnostic tests or 
treatment, representing 
potential events 
Incremental cost-effectiveness ratio 
(ICER) 




Incremental cost divided by 
incremental effectiveness of 
two PE diagnostic strategies 
Invasive pulmonary angiography PA 
(PA) 
Imaging procedure that displays the Invasive test that examines 
blood vessels and organs and uses an blood circulation to the lungs 
injection of a radio contrast agent, X- using radio contrast material, 
ray techniques and a catheter inserted X-ray imaging, and catheter 
into the vein, the heart, and inserted into the vein, the 
pulmonary artery (Ford-Martin, heart, and the pulmonary 
2006; van Loveren et al., 2009) artery 
Event 
A chronological progression 
with events on the left side 
assumed to occur before 
events on the right (Lapin & 
Whisler, 2002) 
ICER 
Cost of strategy A minus cost 
of strategy B divided by 
effectiveness of strategy A 
minus effectiveness of 
strategy B 
PA 
The most accurate PE 
diagnostic test with very high 
sensitivity and specificity 






Decision, Diagnostic, and 
Measuring Tools 
Monte Carlo Simulation (MCS) 
Sensitivity analysis involving 
probability distributions for each 
variable in the decision model 
(Mazur, 2009) 
One-way, two-way and three-way 
sensitivity analyses 
Test of the impact on a decision 
model's outputs by varying the 
values of a variable, or two variables 
or three variables of interest in a 
range of plausible values, while 
holding all other variables constant 
(Sonnenberg, 2009) 
Outcome 
Measurement of the evaluating 
condition (Lapin & Whisler, 2002) 
MCS 
Sensitivity analysis involving 
repeated random sampling 
from input distributions 
assigned for each variable in 
the PE decision model 
One-way, two-way and three-
way sensitivity analyses 
Test of the effect on the PE 
decision tree model results by 
varying values of an uncertain 
variable or two variables or 
three variables with a range of 
plausible values and holding 
all other variables in the 
model constant 
Outcome 
Cost and effectiveness of PE 
diagnostic strategies, e.g., 
dollars per life saved 
MCS 
Input: Probability distributions 
Output: Distribution of 
samples; mean incremental 
cost-effectiveness ratio 
(ICER) 
One-way, two-way and three-
way sensitivity analyses 
Input: Range of plausible 
values and a baseline value 
Output: Error in the model 
results and findings based 
upon the baseline value 
Outcome 
Outcomes or the 
consequences of the events 





Decision, Diagnostic, and 
Measuring Tools 
Parameter estimates 
Determination of parameter estimates 
for variables with uncertainty to use 
them as inputs in the decision tree 
model to conduct a CEA 
Posterior probability 
Likelihood of disease estimated after 
a test is conducted (Jekel et al., 2001) 
Prior probability 
Likelihood of disease estimated 
before a test is conducted (Jekel et 
al.,2001) 
Pulmonary embolism (PE) 
PE is the condition in which clots 
block the pulmonary artery 
(U. S. DHHS, 2008; Virchow, 
1860/2009) 
Parameter estimates 
Determination of estimates by 
applying triangular and y 
distributions to address 
variability to resolve 
uncertainty and eliminate 
error 
Posterior probability 
Estimation of the presence of 
PE after performing PE 
laboratory or imaging tests 
Prior probability 
Estimation of the presence of 
PE before the performance of 
PE diagnostic laboratory or 
imaging tests 
PE 
Diagnostic strategies for early 
diagnosis of PE in patients 
with suspected PE 
Parameter estimates 
Estimation of diagnostic tests' 
costs, sensitivities, 
probabilities, and PE 
diagnostic strategy failure 
rates. 
Posterior probability 
Measured using Bayes's 
theorem 
Prior probability 
Measured by the prevalence of 
PE among patients with 
suspected PE 
PE 
CDR, DD, CT, 
CUS, VQ, PA 






Decision, Diagnostic, and 
Measuring Tools 
Strategy failure rate (SFR) 
The performance of the entire 
strategy 
SFR 
The performance of the five 
investigated PE diagnostic 
strategies 
Treatment (Tr) 
Thrombolytic therapy to dissolve 
blood clots (De Milto & Odle, 2006) 
Ventilation-perfusion (VQ) 
Two imaging procedures: perfusion 
lung scan evaluates blood flow in the 
lungs; ventilation study assesses the 
air space distribution in the lungs 
(Dutton et al., 2009) 
Venous thromboembolism (VTE) 
VTE can be described as the 
condition in which blood clots exist 
in a remote vein 
(U. S. DHHS, 2008) 
Tr 
Anticoagulant treatment 
received by patients with PE 




diagnostic test for detecting 
PE using two imaging 
procedures: ventilation and 
perfusion scanning of PE 
VTE 
VTE includes the medical 
conditions of pulmonary 




mortality rates and three-
month follow-up VTE (i. e. 





Results are read as negative, 
positive, or nondiagnostic for 
PE 
VTE 
CDR, DD, CT, 




The purpose of triangular and y distribution in this dissertation was to determine 
appropriate summary estimates for variables with uncertainty and to use them as inputs in 
the decision free model for conducting a cost-effectiveness analysis. Specific inclusion 
criteria were established for selecting and retaining a study for determining parameter 
estimates by employing triangular and y distributions. They included (a) a publication 
date from January 2000 to December 2010 inclusive, (b) at least one criterion from the 
performance criteria 1 through 5, and (c) criterion 6: 
1. PE CDR, D-dimer test, and CT. 
2. PE CDR, D-dimer test, CT, and CUS. 
3. PE CDR, D-dimer test, CUS, and CT. 
4. PE CDR, D-dimer test, VQ lung scan, and CUS. 
5. PE CDR, D-dimer test, CT, CUS, and PA. 
6. Sufficient information about PE diagnostic strategy failure rates to detect PE 
is provided. 
With regard to sensitivity, specificity, cost, and effectiveness values, a study must 
have satisfied either criterion 7 or 8 or both criteria to be selected for and retained in 
determining parameter estimates by employing triangular and y distributions. 
7. Sufficient information about PE diagnostic test sensitivity and/or specificity 
values was provided. 
8. Sufficient information about costs of a PE diagnostic test or treatment or about 
effectiveness (i. e. strategy failure rates) was provided. 
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There were no restrictions on the type of CDR or PE diagnostic test, hospital 
location, outpatient or inpatient status, gender, age, or total number of patients. 
CEA data. 
Data for direct costs (diagnostic test and treatment) was entered in the decision 
tree model to conduct a CEA. Indirect costs were not included in this study, such as costs 
due to productivity lost, waiting or travelling, or other economic impact on the patients 
and their families as well as the opportunity costs of market competition, income, and 
taxes. Inclusion of indirect costs was unnecessary since this study did not examine the 
well-being of PE patients (i.e., a societal perspective) to assess social welfare 
maximization. Rather, this study focused upon direct costs by examining certain variables 
that affect medical decision-making, not societal decision-making. 
Direct costs data was identified from the literature for the following components 
of PE screening: (a) diagnostic test costs, including laboratory tests costs, imaging tests 
costs, and physician fees for D-dimer test, CT, CUS, VQ lung scan, PA and (b) treatment 
costs, including drugs, laboratory tests performed for monitoring the anticoagulant 
treatment, and physician fees. 
Effectiveness data was entered into the proposed CEA decision tree model to 
detect PE after implementing a strategy. These data included PE detection failure rates, 
which could result in a new PE episode or a fatality. Effectiveness data was identified 
from the literature or was calculated using (a) the three-month follow-up mortality rates 
and (b) the three-month follow-up VTE (i. e. PE and/or DVT) recurrence rates. 
Probabilities data was entered into the proposed CEA decision tree model. These 
probabilities were calculated from several events related to PE diagnostic procedures: (a) 
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ruling out PE after performing a PE diagnostic test, (b) administering treatment after 
performing a PE diagnostic test, and (c) performing an additional PE diagnostic test 
following negative or nondiagnostic results from the previous diagnostic test. 
Research Question and Hypothesis 
Research question. 
To assess the most cost-effective PE diagnostic strategy among five strategies 
currently in use, the following research question was established based upon the CEA 
decision tree model and review of the literature: Which sfrategy offers the best possible 
effectiveness at the lowest or most acceptable cost? 
Hypothesis. 
The null and alternate hypotheses for this CEA were derived from the five PE 
diagnostic strategies investigated. The composition of each strategy involved a CDR and 
a D-dimer test as initial diagnostic procedures followed by one or more imaging tests in 
the described sequence. 
Strategy 1: CDR, D-dimer test, with or without CT; 
Strategy 2: CDR, D-dimer test, CT, with or without CUS; 
Sfrategy 3: CDR, D-dimer test, CUS, with or without CT; 
Sfrategy 4: CDR, D-dimer test, VQ lung scan, with or without CUS; and 
Strategy 5: CDR, D-dimer test, CUS, with or without PA; and 
The following null and alternative hypotheses were investigated. 
Ho: There is no difference in cost-effectiveness among the five PE diagnostic strategies 
investigated. 
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Ha: At least one sfrategy is more cost-effective among the five PE diagnostic strategies 
investigated. 
The following alternative decisions (Dan) based upon the study's hypothesis were 
evaluated: 
Dai: At least strategy 1 is more cost-effective than strategy 2, strategy 3, 
sfrategy 4 and strategy 5. 
Da2: At least sfrategy 2 is more cost-effective than sfrategy 1, strategy 3, 
sfrategy 4 and strategy 5. 
Da3: At least strategy 3 is more cost-effective than strategy 1, strategy 2, 
strategy 4 and strategy 5. 
Da4: At least strategy 4 is more cost-effective than strategy 1, strategy 2, 
strategy 3 and sfrategy 5. 
Das: At least strategy 5 is more cost-effective than strategy 1, strategy 2, 
sfrategy 3 and strategy 4. 
Data Analysis 
Parameter estimates. 
Triangular and y distributions were powerful statistical methods that were 
appropriate for determining parameter estimates for this study. They increased the power 
and precision of the earlier, individual studies that investigated the performance of PE 
diagnostic tests or PE diagnostic strategies. This research suggested that applying 
triangular and y distributions in a CEA to assess parameter estimates of pulmonary 
embolism diagnostic tests' cost, sensitivity and specificity, and effectiveness addressed 
variability in data retrieved from the literature. Additionally, it resolved the uncertainty 
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surrounding the values of cost, effectiveness, and sensitivity and specificity, and it 
eliminated error in the assigned baseline values in the CEA model. For a more detailed 
discussion of triangular and y distributions see Mendenhall and Sincich as well as 
TreeAge Software (Mendenhall & Sincich, 2007; TreeAge Software, 2009). 
CEA methodology. 
CEA techniques mainly were developed during the past four decades, with 
significant research pertaining to cost, effectiveness, incremental cost-effectiveness ratio, 
probabilities, sensitivity analysis, and Monte Carlo Simulation. During the same period, 
CEA techniques concentrating on health issues have been discussed by several authors 
(see Alemi & Gustafson, 2007; Briggs, Goeree, Blackhouse, & O'Brien, 2002; Detsky & 
Naglie, 1990; Drummond, O'Brien, Stoddart, & Torrance, 1997; Gold, 1996; Manly, 
2007; Muennig, 2002, 2008; Pauker & Kassirer, 1978; Porzsolt & Kaplan, 2006; 
Thompson & Nixon, 2005; TreeAge Software, 2009; Willan & Briggs, 2006). 
Cost. Cost data for this study retrieved from the literature are dated and each 
requires an adjustment for inflation (see Drummond et al., 1997; Muennig, 2008; Petitti, 
2000 for a discussion of costs and inflation adjustments). It is assumed that the cost in 
any given year for any PE laboratory test and/or the cost of any PE imaging test can be 
determined and, consequently, adjusted for inflation using information retrieved from the 
medical section of the Consumer Price Index (U. S. Department of Labor, 2011). When 
calculating adjusted costs in years with the inflation rate remaining constant, the equation 
Cn = C0 (l+i)n was appropriate. However, if the rate of inflation fluctuates, the equation 
Cn = Cn-i (l+in) has been found to be more effective in evaluating adjusted cost, where C 
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is the cost and i is the inflation rate for years 1, 2, 3 , . . . and n. Therefore, the adjusted for 
inflation costs for years 1, 2, 3 , . . . and n were determined by the following equations: 
year l :Ci=C 0( l+i i ) 
year2:C2 = Ci(l+i2) 
year3:C3 = C3(l+i3) 
yearn:Cn = Cn-i(l+in) 
Cost data usually has highly skewed distributions; thus, several techniques are 
available for transforming data to produce normality in skewed distributions (see Cohen, 
Cohen, West, & Aiken, 2003; Darren, Mallery, & Briggs, 2003; Field, 2003; Keppel & 
Wickens, 2004; Leech, Barrett, & Morgan, 2008; Maindonald & Braun, 2007; Maxwell 
& Delaney, 2004; Mertler & Vannatta, 2002; Stevens, 2002; Tabachnick & Fidell, 2001; 
Willan & Briggs, 2006). 
Effectiveness. The effectiveness of a given PE diagnostic strategy is typically 
measured by mortality and survival rates (Drummond et al., 1997; Muennig, 2008; Petitti, 
2000). Several authors offered comprehensive mathematical presentation of various 
methods that have been developed to estimate effectiveness (see Drummond et al., 1997; 
Howard, 2009; Muennig, 2008; Petitti, 2000; Willan & Briggs, 2006). Effectiveness in 
this study reflected the performance of each PE diagnostic strategy, including failure 
rates to detect a PE. Sfrategy failure rates represented 3-month follow-up mortality rates 
and 3-month follow-up VTE (i. e. PE or DVT) recurrence rates after implementing a 
specific PE diagnostic strategy in patients with suspected PE. 
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Incremental cost-effectiveness ratio (ICER). CEA using the decision free model 
is a powerful statistical tool that supports complex calculations (see Detsky & Naglie, 
1990; Fenwick, 2009a; Jekel et al., 2001; Miller, 2009; Muennig, 2008; Pauker & 
Kassirer, 1978; Petitti, 2000; van den Hout, 2009). A PE diagnostic strategy was 
considered cost-effective if it meets the general criteria for a cost-effective intervention: 
(a) less expensive and at least as effective; (b) more effective and more expensive, with 
the additional benefit worth the additional cost; (c) less effective and less expensive, with 
the additional benefit of the alternative not worth the additional cost; or (d) cost reduction 
with an equal or improved outcome (Petitti, 2000). 
When PE diagnostic strategy A is more effective but costs more than alternate 
strategy B, the incremental cost-to-incremental effectiveness ratio (ICER) should be 
calculated (Detsky & Naglie, 1990; Fenwick, 2009b; Petitti, 2000). The ICER is 
computed with the following formula: 
LOStstrat:egy A — LOStstratggy 3 
Incremental cost — effectiveness = Effectivenessstrategy A — Effectivenessstrategy B 
PE strategy A is considered the dominant strategy if it is more effective and less 
expensive than alternate strategy B (Muennig, 2008; van den Hout, 2009). This 
relationship is expressed by the following formulas: 
Effectivenessstrategy A > Effectivenessstrategy B 
LOStstrategy A < LOStstrategy B 
PE strategy B is considered the dominated strategy if it is less effective and more 
expensive than alternate strategy A (Muennig, 2008; van den Hout, 2009). This 
relationship is expressed by the following formulas: 
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Effectivenessstrategy B < Effectivenessstrategy A 
Loststrategy g > Coststrategy A 
Event probabilities. Determining event probabilities was essential in CEA that 
incorporates the decision tree model. Probabilities for each possible event and outcome 
not retrieved from the literature were calculated. Two statistical concepts were associated 
with calculating probabilities. For this research, prior probability of PE was an estimate 
of the presence of PE before laboratory or imaging tests were performed. It was derived 
from the estimate of the prevalence of PE among patients with suspected PE (Jekel et al., 
2001; Pauker & Kassirer, 1978). Posterior probability of PE was the estimate of the 
presence of PE after laboratory or imaging tests were performed or after intervention 
(Jekel et al., 2001; Pauker & Kassirer, 1978). Posterior probability estimations for the 
first, second, and further tests were calculated based upon Bayes's theorem (see Bayes, 
1763; Daniel, 2000; Jekel et al., 2001; Pagano & Gauvreau, 2000). Bayes's theorem is 
considered "the foundation for managing and manipulating uncertainty using probability 
theory in expert systems" (Bondi, 2007, p. 32). 
Within the context of the decision tree model, Bayes's theorem can be used to 
answer the following two questions: (a) What is the probability that a patient with a 
positive diagnostic test result has a disease? and (b) What is the probability that the 
patient with a negative diagnostic test result does not have the disease? These questions 
are not answered by either the sensitivity or specificity values of a diagnostic test. 
Assuming that PE+ is an event in which a patient has PE and PE- is an event in which a 
patient does not have PE, then the posterior probability for a positive PE diagnostic test is 
established using the following formula, 
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p(PE+/T+) = [p(T+/PE+)p(PE+)]/[p(T+/PE+)p(PE+)+p(T+/PE-)p(PE-)]. 
The posterior probability for a negative PE diagnostic test is determined using this 
formula: 
p(PE-/T-) = [p(T-/PE-)p(PE-)]/[p(T-/PE-)p(PE-)+p(T-/PE+)p(PE+)]. 
The letter p indicates probability, T+ indicates that a specific PE diagnostic test is 
positive, T- indicates that the specific PE diagnostic test is negative, and the diagonal line 
(/) indicates conditional upon that which follows. 
Monte Carlo Simulation Sensitivity Analysis: A Probabilistic Approach 
A sensitivity analysis was conducted using a probabilistic approach through a 
Monte Carlo simulation (see Bondi, 2007; Manly, 2007; Muennig, 2008; TreeAge 
Software, 2009). This method, which was named for the European gambling 
establishment, considered probability distributions for each variable in the decision tree 
model. A mean and 95% CI for the variable of interest was obtained by sampling each 
distribution repeatedly for the overall cost, effectiveness, and incremental cost-
effectiveness ratio by diagnostic strategy. Available software (TreeAge Software, 2009) 
that applies a Monte Carlo simulation offers the option to select the input distribution for 
each variable from a large number of distributions. As a result, the simulation provided 
the final distribution of each variable as well as the final distribution of incremental cost-
effectiveness values on a normal distribution, one of the most commonly used 
distributions in probability theory and statistics (see Daniel, 2000; Howell, 2002; Kuzma 
& Bohnenblust, 2001; Pagano & Gauvreau, 2000; TreeAge Software, 2009). 
In the Monte Carlo simulation, the inputs in the decision tree model function as 
variables that can indicate a wide range of values, instead of fixed numbers and can allow 
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all variable uncertainties to be included in the analysis while reproducing the model 
multiple times. The advantages of this simulation included testing all variables 
simultaneously, providing the mean and standard deviation, and generating a confidence 
interval for the expected outcomes (i.e., cost, effectiveness, and cost-effectiveness ratio). 
A Monte Carlo simulation significant at a (alpha) level of .05 required a minimum of 
1,000 sets of simulated data, and a simulation significant at a level of .01 required a 
minimum of 5,000 sets of simulated data (Manly, 2007). The a level for this research was 
set at .05. 
The software used in this study (TreeAge Software, 2009) performs CEAs using 
the decision free model. It allowed the researcher to conduct Monte Carlo Simulations as 
well as one-way, two-way, and three-way sensitivity analyses. It exported to Microsoft 
Excel and allowed the production of several charts for the input distributions, the 
distribution of outcomes, and the distribution of the incremental outcomes. 
One-Way, Two-Way, and Three-Way Sensitivity Analyses: A Deterministic 
Approach 
In this research, the CEA combined effectiveness data and cost data of PE 
diagnostic sfrategies retrieved from studies identified in the literature. Inferential 
uncertainty due to possible errors within the data was addressed using a one-way, two-
way and three-way sensitivity analysis that assessed the effect of varying model 
assumptions on the findings (Muennig, 2008; Petitti, 2000; Willan & Briggs, 2006). The 
decision tree CEA model was tested using this sensitivity analysis. 
In a one-way, two-way, and three-way sensitivity analysis, a single variable, or a 
pair of variables or a group of three variables, respectively, was tested within a range of 
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reasonable values while all other variables were held constant. Variables for which there 
was uncertainty were tested using a wide range of values from much lower to much 
higher than the baseline estimate. Variables for which there was less uncertainty, hence 
more confidence, were tested using a narrower range of values. If a PE diagnostic 
strategy remained dominant within a range of plausible values for inputs involving 





The purpose of this study was to assess the most cost-effective diagnostic 
strategy, among several strategies currently in use for patients with suspected pulmonary 
embolism (PE), based upon sfrategy failure rates. This chapter examines the parameter 
estimates, the comparisons of decision's alternative, and the sensitivity analysis results. 
First, parameter estimates were assessed based upon data retrieved from the literature 
with regards to PE diagnostic test direct costs, effectiveness of PE diagnostic strategies as 
well as PE diagnostic tests' sensitivity and specificity. Second, alternative decisions 
addressing PE diagnostic strategies were evaluated to determine which strategy exerted 
influence on the medical decision-making process. Third, Monte Carlo probabilistic 
sensitivity analyses and one-way, two-way, and three-way deterministic sensitivity 
analyses were conducted to assess the impact of uncertainty on the cost-effectiveness 
analysis (CEA) model. Finally, it was determined that Strategy 3, comprising a clinical 
decision rule (CDR), a D-dimer test (DD), a compression ulfrasonography (CUS), and a 
computed tomography pulmonary angiography (CT), was the most cost effective. This 
strategy was compared to alternate strategy 1, comprising a CDR, a DD, and a CT; 
alternate strategy 2, comprising a CDR, a DD, a CT, and a CUS; alternate strategy 4, 
comprising a CDR, a DD, a VQ lung scan, and a CUS; and alternate strategy 5, 
comprising a CDR, a DD, a CT, a CUS, and a PA. 
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Parameter Estimates Results 
Pulmonary embolism diagnostic tests and treatment direct costs. 
A literature review was conducted to obtain PE diagnostic tests and treatment 
direct costs. The predetermined inclusion criteria were met only by five studies 
appropriate for inclusion in the analysis. Of them, three are cost-effectiveness analysis 
(CEA) studies, one is a management study, and one is an economic review. A list of 
studies included in the analysis is presented in Table 9. 
Table 9 














































Note. PE = pulmonary embolism; DD = D-dimer test; CT = computed tomography pulmonary 
angiography; CUS = compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive 
pulmonary angiography; Tr = treatment for PE. 
Since the annual inflation rates differ, substantially among the years between 
1998 and 2010 the direct costs, adjusted for inflation, were determined by the equation 
Cn= Cn-i(l+in), where C is the cost and i is the inflation rate for years 1, 2, 3 , . . . , and n. 
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Estimations were based upon the studies included in the analysis, while the 
Bureau of Labor Statistics within the U.S. Department of Labor provided the Consumer 
Price Index for hospital and related services (U. S. Department of Labor, 2011). 
Comparisons among the adjusted-for-inflation PE diagnostic testing cost during the 
period from 1998 through 2010 are presented in Figures 3 through 8. The frend line 
equations and r2 values for the PE diagnostic testing costs adjusted for inflation are 
presented in Tables 10 through 15. 
D-dimer test (DD) adjusted costs increased linearly during the years 1998-2010 
with trend line equation R2 values of more than 98% (see Table 10). The range from the 
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Figure 3. Comparisons of D-dimer test (DD) direct cost for the years 1998-2010 adjusted 
for inflation. 
Table 10 
Trend Line Equations and R Values ofDD Cost Adjusted for Inflation 
D-dimer (DD) 
Adjusted Cost 1 
Adjusted Cost 2 










Study of Unadjusted Cost 
First Author Year 
Van Erkel 1999 
Duriseti 2006 
Stein 2006 
Note. Y = adjusted cost; x = time. 
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Computed tomography pulmonary angiography (CT) adjusted costs increased 
linearly during the years 1998-2010 with trend line equation R2 values of more than 98% 
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Figure 4. Comparisons of computed tomography pulmonary angiography (CT) direct 
cost for the years 1998-2010 adjusted for inflation. 
Table 11 
Trend Line Equations and R Values ofCT Cost Adjusted for Inflation 
Adjusted Cost Study of Unadjusted Cost 
CT Equation R^  First Author Year 
Adjusted Cost 1 YCTi=12.445x+l 13.28 RCTI=0.9872 Van Erkel 
Adjusted Cost 2 YCT2=32.044x+267.99 RCT2=0.9924 Paterson 
Adjusted Cost 3 YCT3=39.993x+239.61 RcT3=0.9946 Doyle 
Adjusted Cost 4 YCT4=15.559x+72.024 RcT4=0.9994 Duriseti 






Note. CT = computed tomography pulmonary angiography; Y = adjusted cost; x = time. 
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Compression ultrasonography (CUS) adjusted costs increased linearly during the 
years 1998-2010 with trend line equation R2 values of more than 98% (see Table 12). The 
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Figure 5. Comparisons of compression ultrasonography (CUS) direct cost for the years 
1998-2010 adjusted for inflation. 
Table 12 
Trend Line Equations and R Values of CUS Cost Adjusted for Inflation 
Adjusted Cost Study of Unadjusted Cost 
CUS Equation Rz First Author Year 
Adjusted Cost 1 
Adjusted Cost 2 
Adjusted Cost 3 
Adjusted Cost 4 
















Note. CUS = compression ultrasonography; Y = adjusted cost; x = time. 
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Ventilation-perfusion lung scan (VQ) adjusted costs increased linearly during the 
years 1998-2010 with trend line equation R2 values of more than 98% (see Table 13). The 
range from the lowest-to-highest VQ adjusted cost range was $824 (see Figure 6). 
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Figure 6. Comparisons of ventilation-perfusion lung scan (VQ) direct cost for the years 
1998-2010 adjusted for inflation. 
Table 13 
Trend Line Equations and R Values of VQ Cost Adjusted for Inflation 
Adjusted Cost Study of Unadjusted Cost 
VQ Equation Rz First Author Year 
Adjusted Cost 1 YVQi=62.963x+258.3 RVQi=0.9872 Van Erkel 
Adjusted Cost 2 YVQ2=42.536x+143.06 RVQ2=0.9924 Paterson 
Adjusted Cost 3 YVQ3=31.994x+31.714 RVQ3=0.9946 Doyle 
Adjusted Cost 4 YVQ4=54.458x-20.204 RVQ4=0.9994 Duriseti 






Note. VQ = ventilation-perfusion lung scan; y = adjusted cost; x = time. 
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Invasive pulmonary angiography (PA) adjusted costs increased linearly during the 
years 1998-2010 with trend line equation R2 values of more than 98% (see Table 14). The 
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Figure 7. Comparisons of invasive pulmonary angiography (PA) direct cost for the years 
1998-2010 adjusted for inflation. 
Table 14 
Trend Line Equations and R Values of PA Cost Adjusted for Inflation 
PA 
Adjusted Cost 1 
Adjusted Cost 2 
Adjusted Cost 3 























Note. PA = invasive pulmonary angiography test; Y = adjusted cost; x = time. 
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PE treatment adjusted costs increased linearly during the years 1998-2010 with 
trend line equation R2 values of more than 99% (see Table 15). The range from the 
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Figure 8. Comparisons of PE treatment (Tr) direct cost for the years 1998-2010 adjusted 
for inflation. 
Table 15 
Trend Line Equations and R Values of Treatment Cost Adjusted for Inflation 
Treatment (Tr) 
Adjusted Cost 1 








Study of Unadjusted cost 
First Author Year 
Van Erkel 1999 
Duriseti 2006 
Note. Y = adjusted cost; x = time. 
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In general, considerable differences among PE diagnostic testing costs were 
identified in the literature. Therefore, to resolve the uncertainty surrounding the costs of 
these tests, triangular disfributions were applied based upon the adjusted cost estimations 
presented. D-dimer test direct costs ranged from $25 to $33 with an expected value of 
$28.3 (see Figure 9). The cumulative probability within the first 10th percentile indicated 
DD costs at approximately $26.3 or less. At the 50th percentile, the median DD cost was 
approximately $28.1, while at or above the 90th percentile DD costs were approximately 
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Figure 10. D-dimer test (DD) direct cost cumulative probability. 
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The computed tomography pulmonary angiography (CT) direct costs ranged from 
$275 to $2,387, with an expected value of $1,121 (see Figure 11). The cumulative 
probability within the 10th percentile revealed that CT direct costs were approximately 
$572.5 or less. At the 50th percentile, the median CT cost was about $1,051.6, while at 
and above the 90th percentile CT costs were $1,792.2 or greater (see Figure 12). 
270 0 870 0 1470 0 2070 0 
Value 

















Figure 12. Computed tomography pulmonary angiography (CT) direct cost cumulative 
probability. 
90 
The compression ultrasonography (CUS) direct cost values ranged from $137 to 
$432 with an expected value of $292 (see Figure 13). The cumulative probability within 
the 10th percentile indicated that CUS direct costs were approximately $207.8 or less. At 
the 50th percentile, the median CUS cost was $294.8 while at and above the 90th 
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Figure 13. Compression ultrasonography (CUS) direct cost triangular distribution. 
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Figure 14. Compression ulfrasonography (CUS) direct cost cumulative probability. 
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The ventilation-perfusion lung scan (VQ) direct costs ranged from $612 to $1,436 
with an expected value of $1,003 (see Figure 15). The cumulative probability within the 
10* percentile revealed that VQ costs were approximately $782.4 or less. At the 50th 
percentile, the median VQ cost was about $994.7, while at or above the 90th percentile 
the VQ costs were approximately $1,237.6 or greater (see Figure 16). 
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Figure 16. Ventilation-perfusion lung scan (VQ) direct cost cumulative probability. 
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The invasive pulmonary angiography (PA) direct costs ranged from $1,072 to 
$8,381 with an expected value of $3,676 (see Figure 17). The cumulative probability at 
the first 10th percentile revealed that the costs were approximately $1,689.02 or less. At 
the 50th percentile, the median PA cost was about $3,383.0, while at and above the 90th 
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Figure 17. Invasive pulmonary angiography (PA) direct cost triangular distribution. 
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Figure 18. Invasive pulmonary angiography (PA) direct cost cumulative probability. 
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The direct costs of PE treatment ranged from $1,449 to $1,640 with an expected 
value of $1,545 (see Figure 19). The cumulative probability at the first 10th percentile 
indicated that PE treatment cost was $1,491.8 or less. At the 50th percentile, the median 
cost of treatment was $1,544.7, while at or above the 90th percentile treatment cost values 
were roughly $1,597.4 or greater (see Figure 20). 





























Figure 20. PE treatment (Tr) direct cost cumulative probability. 
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Table 16 presents a summary of the results of the triangular distribution expected 
values and statistics of PE diagnostic testing direct costs adjusted for inflation. 
Table 16 































Note. PE = pulmonary embolism; DD = D-dimer test; CT = computed tomography pulmonary 
angiography; CUS = compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive 
pulmonary angiography; Tr = treatment. Costs are in dollars. 
Effectiveness of pulmonary embolism diagnostic strategies. 
A literature review of the research regarding the effectiveness of the strategies 
employed to diagnose PE was conducted. Of the studies identified, 233 had potential 
relevance for strategy 1, 99 had potential relevance for strategy 2, 97 for strategy 3, 47 
for sfrategy 4, and 7 articles had potential relevance for sfrategy 5. The predetermined 
inclusion criteria were met by six studies addressing strategy 1, two studies discussing 
strategy 2, three studies concerning sfrategy 3, four studies examining strategy 4, and two 
studies reviewing strategy 5. A summary of the numbers of articles included in the 
process to obtain PE diagnostic strategy effectiveness values is presented in Table 17. 
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Table 17 
Summary of Articles Evaluated for Inclusion in the Review ofPE Diagnostic Strategy 
Effectiveness 
Categories of Evaluation Strategy 1 Strategy 2 Strategy 3 Strategy 4 Strategy 5 
Potentially Relevant Articles 233 99 97 47 7 
Identified 
Articles not Related to PE Test for 202 78 74 29 2 
PE Diagnosis 
Articles Related to PE Test for PE 31 21 23 18 5 
Diagnosis In Ex In Ex In Ex In Ex In Ex 
6 25 2 19 3 20 4 14 2 3 
Note. PE = pulmonary embolism; Strategy 1 = a CDR, a D-dimer test, and a CT; Strategy 2 = a CDR, a D-
dimer test, a CT, and a CUS; Strategy 3 = a CDR, a D-dimer test, a CUS, and a CT; Strategy 4 = a CDR, a 
D-dimer test, a VQ, and a CUS; Strategy 5 = a CDR, a D-dimer test, a CT, a CUS, and a PA. CDR = 
clinical decision rule; CT = computed tomography pulmonary angiography; CUS= compression 
ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive pulmonary angiograph. In = 
included articles related to PE test for PE diagnosis that met inclusion criteria; Ex = excluded articles 
related to PE test for PE diagnosis that did not meet inclusion criteria. 
Studies used in the analysis of PE diagnostic strategy effectiveness, including the 
total number of participants as well as effectiveness levels expressed as failure rates, are 
presented in Table 18. Differences in the PE diagnostic strategy failure rates were 
identified in the literature. To resolve the uncertainty surrounding those failure rates, y 
disfributions were applied based upon failure rate estimations (see Table 18). The y 
distribution expected values of the strategy failure rates to detect PE demonstrated very 
small differences expressed within a .553329 range between a high of 1.099999 and a 
low of 0.546667. Specifically, strategy 3 achieved the lowest expected failure rate of 
96 
0.546667. A summary of the y distribution strategy failure rates statistics for the studies 
included in this analysis is presented in Table 19. 
Table 18 






Strategy Failure rates (% 
Level 1 Level 2 Level 3 
Rate < 0.50 0.50 < Rate < 1.00 1.00 <Rat e 
Ghanima, 2005 1 432 
Hogg, 2006 1 408 
van Belle, 2006 1 3306 
Nijkeuter, 2007 1 3306 
Righini, 2008 1 838 
Eng, 2009 1 219 
Anderson, 2005 2 & 5 858 
Perrier, 2005 2 & 5 756 
Elias, 2005 3 274 
Perrier 2004 3 965 
Righini, 2008 3 855 
Wells, 2001 4 930 
ten Wolde, 2004 4 631 
Kearon, 2006 4 1126 
Anderson, 2007 4 712 
Anderson, 2005 5 & 2 858 


















Note. PE = pulmonary embolism; SFR 1 = strategy failure rate level 1 < 0.50%; SFR 2 = 0.50 % < strategy 
failure rate level 2 < 1.00%; SFR 3 = 1.00% < strategy failure rate level 3. 
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Table 19 





































































Note. PE = pulmonary embolism; Strategy 1 = a CDR, a D-dimer test, and a CT; Strategy 2 = a CDR, a D-
dimer test, a CT, and a CUS; Strategy 3 = a CDR, a D-dimer test, a CUS, and a CT; Strategy 4 = a CDR, a 
D-dimer test, a VQ, and a CUS; Strategy 5 = a CDR, a D-dimer test, a CT, a CUS, and a PA. CDR = 
clinical decision rule; CT = computed tomography pulmonary angiography; CUS= compression 
ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive pulmonary angiography. 
Sensitivity and specificity of pulmonary embolism diagnostic tests. 
A literature review of articles investigating sensitivity and specificity values of 
tests to diagnose PE was conducted. Of the 354 articles examining the D-dimer test, 55 
addressed sensitivity and specificity values. Of the 517 articles addressing the CT, 28 
reviewed sensitivity and specificity. The VQ lung scan diagnostic test was examined in 
203 articles: 14 addressed specificity and sensitivity. Six of the 270 CUS studies 
addressed sensitivity and specificity, and four of the 119 articles presenting PA as a PE 
98 
diagnostic tool examined these values. A summary of the articles considered for inclusion 
in the review process for obtaining sensitivity and specificity values is presented in Table 
20. A list of studies analyzed to obtain PE diagnostic test sensitivity and specificity 
values is presented in Table 21. 
Table 20 
Summary of Articles Evaluated for Inclusion in the Review ofPE Test Sensitivity and 
Specificity 
Categories of Evaluation DD CT VQ CUS PA 
Potentially Relevant Articles 354 517 203 270 119 
Identified 
Articles not Related to PE Test for 193 403 133 226 108 
PE Diagnosis 
Articles Related to PE Test for PE 161 114 70 44 11 
Diagnosis In Ex In Ex In Ex In Ex In Ex 
55 106 28 86 14 56 6 38 4 7 
Note. PE = pulmonary embolism; DD = D-dimer test; CT = computed tomography pulmonary 
angiography; VQ = ventilation-perfusion lung scan; CUS= compression ultrasonography; PA = invasive 
pulmonary angiography. In = included articles related to PE test for PE diagnosis that met inclusion 
criteria; Ex = excluded articles related to PE test for PE diagnosis that did not meet inclusion criteria. 
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Table 21 



















































































































































































Table 21 (continued) 
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Study First Year Type Study First Year Type Study First Year Type 
Author Author Author 





















































































































































Invasive Pulmonary Angiography (PA) 
Perrier 2003 CEA Van Erkel 1999 E 
Larcos 2000 CEA Stein 1992 M 
Note. PE = pulmonary embolism; M = diagnostic management; R = review; Meta = meta-analysis; CEA = 
cost-effectiveness analysis; E = economical study. 
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The sensitivity and specificity values identified in the literature for the various PE 
diagnostic tests reveal significant differences. To resolve the uncertainty surrounding the 
values, y disfributions were applied based upon data retrieved from the cited studies. The 
y distribution expected values for the PE diagnostic tests illustrated a very high sensitivity 
and a very low specificity level for the D-dimer test; a moderate sensitivity and a high 
specificity level for the CT, the CUS, and the VQ lung scan; and very high sensitivity and 
specificity levels for the PA. The PA demonstrated the highest sensitivity and specificity 
values of all the diagnostic tests. Table 22 presents a summary of the results of the y 
distribution sensitivity and specificity expected values from the PE diagnostic test studies 
included in this analysis. 
Table 22 
Expected y Distribution Sensitivity and Specificity Values ofPE Diagnostic Tests (in 
Percentage) 
PE Diagnostic Test Expected Sensitivity Expected Specificity 
DD 95.17436 47.77547 
CT 88.11154 94.56923 
CUS 89.95000 94.90000 
VQ 82.77500 90.49999 
PA 97.24999 97.00000 
Note. PE = pulmonary embolism; DD = D-dimer test; CT = computed tomography pulmonary 
angiography; CUS= compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive 
pulmonary angiography. Five sensitivity and specificity levels were established: very low with a value less 
than 60%), low with a value between 60 and 19.99%, moderate with a value between 80 and 89.99%), high 
with a value between 90 and 95.99%, and very high with a value between 96 and 100%. 
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The y distribution mean sensitivity values of the PE diagnostic tests illustrated the 
lowest sensitivity level for the VQ lung scan followed by the CT, the CUS, and the DD, 
while the PA demonstrated the highest sensitivity level. Table 23 presents a summary of 
the results of the sensitivity y distribution statistics for studies included in this analysis. 
Table 23 











































































Note. PE = pulmonary embolism; DD = D-dimer test; CT 
angiography; CUS = compression ultrasonography; VQ = 
pulmonary angiography. 
= computed tomography pulmonary 
ventilation-perfusion lung scan; PA = invasive 
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The y distribution mean specificity values of the PE diagnostic tests illustrated the 
lowest specificity level for the DD followed by the VQ lung scan, the CT, and the CUS. 
The PA test demonsfrated the highest specificity level. Table 24 presents a summary of 
the results of the specificity y distribution statistics of the studies included in this 
analysis. 
Table 24 











































































Note. PE = pulmonary embolism; DD = D-dimer test; CT 
angiography; CUS = compression ultrasonography; VQ = 
pulmonary angiography. 
= computed tomography pulmonary 
ventilation-perfusion lung scan; PA = invasive 
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Evaluation of Alternative Decisions (Da„) 
The cost-effectiveness analysis (CEA) revealed that alternative decision 3 (Da3) 
was accepted, while all other alternatives were rejected. Alternative decision 3 stated that 
at least strategy 3, composed by a CDR, a DD, a CUS, and a CT, would be more cost-
effective than strategy 1, strategy 2, strategy 4, or sfrategy 5. The results of this 
evaluation are summarized in Table 25. 
Table 25 
Summary of Alternative Decisions Evaluation 
Alternative 
Decision 

















Strategy 1 vs. all other strategies 
Strategy 2 vs. all other strategies 
Strategy 3 vs. all other strategies 
Strategy 4 vs. all other strategies 
Strategy 5 vs. all other strategies 
Note. Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS; Strategy 3 = a 
CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a CDR, a DD, a 
CT, a CUS, and a PA. CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography 
pulmonary angiography; CUS = compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = 
invasive pulmonary angiography; CEA = cost-effectiveness analysis; Dan = alternative decision. 
Detailed evaluation. 
The CEA model was applied to a decision tree, and all five strategies were 






CDR.DD ng no Tr 
pi 
CT p do Tr 
sCDR,DO p do CT 
P2 
CDR.DD ng no Tr 
p3 
CT ng no Tr 
p4 
pi 
CT p do Tr 
VCDR.DD p do CT 
p2 
CDR, DD ng no Tr 
p3 
XT ng do CUS 
CUS p do Tr 
-O pS CUS ng no Tr 
pe 
pi 
CUS p do Tr 
VCDR,DD p do CUSr 
P2 
CDR, DD ng no Tr 
pT 
CT p do Tr 
SCUS ng do CT 
p8 
P9 
CT ng no Tr 
p10 
VQ p do Tr 
VCDR,DD p do VQ( 
P2 
CDR.DD ng no Tr 
pn 
CUS p do Tr 
, VQ p ng do CUS 
p12 o 
p13 
CUS ng no Tr 
p14 
p1 
CT p do Tr 
VCDR,DD p do CT 
P2 
p3 
VCT ng do CUS 
CUS p doTr 
ps 










< ] c11/e11 
-<c12/e12 
<]c13/e13 





PA p doTr 
^CUS ng do PA„ 
p8 
p15 




Figure 21. Decision tree CEA model of five PE diagnostic strategies. CEA = cost-
effectiveness analysis; PE = pulmonary embolism; Strategy 1 = a CDR, a DD, and a CT; 
Sfrategy 2 = a CDR, a DD, a CT, and a CUS; Strategy 3 = a CDR, a DD, a CUS, and a 
CT; Strategy 4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a CDR, a DD, a CT, a 
CUS, and a PA. CDR = clinical decision rule; DD = D-dimer test; CT = computed 
tomography pulmonary angiography; CUS = compression ulfrasonography; VQ = 
ventilation-perfusion lung scan; PA = invasive pulmonary angiography; Tr = treatment; 
ng = negative; p = positive; pn = probability; c = cost payoffs; e = effectiveness payoffs. 
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Strategy 1, comprising a CDR, a DD, and a CT, appeared in the first arm of the 
decision tree. The costs associated with strategy 1 were defined by appropriate triangular 
distributions (i.e., cl, c2, and c3). The effectiveness associated with strategy 1 was 
defined by appropriate y distributions (i.e., el, e2, and e3). The event probabilities for 
strategy 1 were defined by appropriate Bayes's applications (i.e., pi, p2, p3, and p4). 
Sfrategy 2, comprising a CDR, a DD, a CT, and a CUS, appeared in the second arm of 
the decision tree. The costs associated with strategy 2 were defined by appropriate 
triangular distributions (i.e., c4, c5, c6, and c7). The effectiveness associated with 
strategy 2 was defined by appropriate y distributions (i.e., e4, e5, e6, and e7). The event 
probabilities for strategy 2 were defined by appropriate Bayes's applications (i.e., p i , p2, 
p3, p4, p5, and p6). Strategy 3, comprising a CDR, a DD, a CUS, and a CT, appeared in 
the third arm of the decision tree. The costs associated with strategy 3 were defined by 
appropriate triangular disfributions (i.e., c8, c9, clO, and cl 1). The effectiveness 
associated with strategy 3 was defined by appropriate y distributions (i.e., e8, e9, elO, and 
el l ) . The event probabilities for sfrategy 3 were defined by appropriate Bayes's 
applications (i.e., pi, p2, p7, p8, p9, and pi0). Strategy 4, comprising a CDR, a DD, a 
VQ, and a CUS, appeared in the fourth arm of the decision tree. The costs associated with 
strategy 4 were defined by appropriate triangular distributions (i.e., cl2, cl3, cl4, and 
cl5). The effectiveness associated with strategy 4 was defined by appropriate y 
disfributions (i.e., el2, el3, el4, and el5). The event probabilities for sfrategy 4 were 
defined by appropriate Bayes's applications (i.e., pi, p2, pi 1, pl2, pl3, and pl4). 
Sfrategy 5, comprising a CDR, a DD, a CT, a CUS, and a PA, appeared in the last arm of 
the decision tree. The costs associated with strategy 5 were defined by appropriate 
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triangular distributions (i.e., cl6, cl7, cl8, cl9, and c20). The effectiveness associated 
with strategy 5 was defined by appropriate y distributions (i.e., el 6, el7, el 8, el9, and 
e20). The event probabilities for this strategy were defined by appropriate Bayes's 
applications (i.e., pi , p2, p3, p4, p5, p6, pl5, and pl6). 
CEA results revealed that strategy 3 was the most cost-effective of the sfrategies. 
Strategy 5 was cost-effective; however, strategies 1, 2 and 4 were not cost-effective and 
were dominated by strategy 3. The lowest cost was demonstrated by strategy 3, followed 
by strategies 1, 4, 2, and 5, respectively. Conversely, the highest effectiveness was 
demonstrated by strategy 5, followed by strategies 3, 4, 2, and 1, in that order. The lowest 
cost-effectiveness ratio was demonsfrated by strategy 3, followed in order by sfrategies 1, 
4, 2, and 5. Table 26 summarizes cost-effectiveness analysis results. 
Table 26 















































Note. Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS; Strategy 3 = a 
CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a CDR, a DD, a 
CT, a CUS, and a PA. CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography 
pulmonary angiography; CUS = compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = 
invasive pulmonary angiography; C/E = cost-effectiveness ratio; C-E = cost-effective strategy; ALS = 
additional lives saved. 
The CEA of the five PE diagnostic strategies revealed that strategies 3 and 5 
formed a cost-effectiveness frontier. Strategies 1, 2, and 4 were to the left of this frontier 
line with higher costs and lower effectiveness levels, indicating domination by strategy 3. 
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Figure 22. Cost-effectiveness analysis for five PE diagnostic strategies. Sfrategy 1 = a 
CDR, a DD and a CT; Sfrategy 2 = a CDR, a DD, a CT, and a CUS; Strategy 3 = a CDR, 
a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a 
CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule; DD = D-dimer test; 
CT = computed tomography pulmonary angiography; CUS = compression 
ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive pulmonary 
angiography; ALS = additional lives saved. 
Individual cost and effectiveness pairs for each recalculation of the model are 
presented in the cost-effectiveness scatter plot with a different color representing each 
sfrategy (see Figure 23). Strategy 1 cost-effectiveness dots formed an area similar to a 







formed an area similar to a rectangle, indicating a wide range of costs and a narrow range 
of effectiveness values. Strategy 3 and 4 dots were concentrated in a small area similar to 
a circle, indicating a narrow range of both costs and effectiveness values. Strategy 5 dots 
formed an area similar to a rectangle, indicating a wide range of costs and a narrow range 
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Figure 23. Cost and effectiveness scatter plot by strategy. 1 = strategy 1; 2 = strategy 2; 3 
= sfrategy 3; 4 = strategy 4; 5 = sfrategy 5; Strategy 1 = a CDR, a DD and a CT; Sfrategy 
2 = a CDR, a DD, a CT, and a CUS; Strategy 3 = a CDR, a DD, a CUS, and a CT; 
Strategy 4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a CDR, a DD, a CT, a CUS, 
and a PA. CDR= clinical decision rule; DD = D-dimer test; CT = computed tomography 
pulmonary angiography; CUS = compression ultrasonography; VQ = ventilation-
perfusion lung scan; PA = invasive pulmonary angiography; ALS = additional lives 
saved. 
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Results by alternative decision (Da„). 
Dai: At least sfrategy 1 will be more cost-effective than strategy 2, strategy 3, 
strategy 4, or strategy 5. 
This alternative decision is rejected. Strategy 1, comprising a CDR, a DD, and a 
CT, with a cost of about $1,952.98 and an effectiveness level of 99.78456 was dominated 
by strategy 3 (see Table 26). Results for the costs, effectiveness, and cost-effectiveness 
ratio of PE diagnostic strategy 1 are presented in Table 27. 
Table 27 



























Note. PE = pulmonary embolism; Strategy 1 = a CDR, a DD and a CT. CDR = clinical decision rule; DD = 
D-dimer test; CT = computed tomography pulmonary angiography; ALS = additional lives saved. 
In strategy 1, the lowest cost was associated with a negative DD not requiring 
treatment, while the most expensive cost was associated with the combination of a 
positive DD and a positive CT requiring treatment. Specifically, the overall cost of a 
negative DD not requiring treatment was $28 (cl). The overall cost of a positive DD 
followed by a positive CT requiring treatment was $2,694 (c2). The overall cost of a 
I l l 
positive DD and a negative CT was $1,150 (c3). The DD and CT branches of sfrategy 1 
are presented in Figure 24. 
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Figure 24. Decision tree CEA model arm for PE diagnostic strategy 1. CEA = cost-
effectiveness analysis; PE = pulmonary embolism; Strategy 1 = a CDR, a DD and a CT. 
CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography pulmonary 
angiography; Tr = treatment; ng = negative; p = positive; pn = probability; c = cost 
payoffs; e = effectiveness payoffs. 
The confidence ellipse on the cost-effectiveness plane in Figure 25a illustrates the 
region that contains 95% uncertainty surrounding cost and effectiveness comparators of 
strategy 1 vs. strategy 3. The dots in the confidence ellipse represent the individual 
incremental cost and incremental effectiveness pairs for each recalculation of the model. 
The dots in the confidence ellipse in the upper left (north-west) quadrant of the cost-
effectiveness plane demonstrate that strategy 1 was less effective and more costly than 
strategy 3. Thus, strategy 3 dominates strategy 1. The dots of the confidence ellipse in the 
lower left (south-west) quadrant of the cost-effectiveness plane indicate that strategy 1 
was less effective and less costly than strategy 3. Thus, sfrategy 3 is optimal. The lower 
and upper 95% confidence interval limits of the ICER were -5909 and 4015, respectively, 
based upon the 2.5th and 97.5th probability distribution percentiles. 
The isocontours in Figure 25b illustrate the regions that correspond to 10 regions 
of similar frequency of incremental cost and incremental effectiveness of strategy 1 vs. 
strategy 3. When the lines are close together, the magnitude of the slope is large, 
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indicating steep variation. The willingness-to-pay line intersects the x and y axes at the 
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Figure 25. Incremental cost and effectiveness (ICE) scatter plot and isocontours graphs 
of sfrategy 1 vs. strategy 3. Strategy 1 = a CDR, a DD and a CT; Sfrategy 3 = a CDR, a 
DD, a CUS, and a CT. CDR = clinical decision rule; DD = D-dimer test; CT = computed 
tomography pulmonary angiography; CUS = compression ultrasonography; ALS = 
additional lives saved. 
Da2: At least strategy 2 will be more cost-effective than strategy 1, strategy 3, 
strategy 4, or strategy 5. 
This alternative decision is rejected. Strategy 2, comprising a CDR, DD, a CT, 
and a CUS, with a cost of $2,441.23 and an effectiveness level of 99.91172 was 
dominated by strategy 3 (see Table 26). Results for the costs, effectiveness, and cost-
effectiveness ratio of PE diagnostic strategy 2 are presented in Table 28. 
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Table 28 


























Note. PE = pulmonary embolism; Strategy 2 = a CDR, a DD, a CT, and a CUS. CDR = clinical decision 
rule; DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS = compression 
ultrasonography; C/E = cost-effectiveness ratio; ALS = additional lives saved. 
In strategy 2, the lowest cost was associated with a negative DD not requiring 
treatment. The most expensive cost was associated with the combination of a positive 
DD, a negative CT, and a positive CUS requiring treatment. The overall cost of a 
negative DD was $28 (c4). The overall cost of a positive DD followed by a positive CT 
requiring freatment was $2,694 (c5). The overall cost of a positive DD, a negative CT, 
and a positive CUS requiring treatment was $2,986 (c6). The overall cost of a positive 
DD, a negative CT, and a negative CUS was $1,441 (c7). The DD, CT, and CUS 
branches of strategy 2 are presented in Figure 26. 
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Figure 26. Decision tree CEA model arm for PE diagnostic strategy 2. CEA = cost-
effectiveness analysis; PE = pulmonary embolism; Strategy 2 = a CDR, a DD, a CT, and 
a CUS. CDR= clinical decision rule; DD = D-dimer test; CT = computed tomography 
pulmonary angiography; CUS= compression ultrasonography; Tr = treatment; ng = 
negative; p = positive; pn = probability; c = cost payoffs; e = effectiveness payoffs. 
The confidence ellipse on the cost-effectiveness plane in Figure 27a illustrates the 
region that contains 95% uncertainty surrounding cost and effectiveness comparators of 
strategy 2 vs. strategy 3. The dots in the confidence ellipse are located in the upper left 
(north-west) quadrant of the cost-effectiveness plane. This indicates that strategy 2 was 
less effective and more costly than strategy 3. Thus, strategy 3 dominates strategy 2. The 
lower and upper 95% confidence interval limits of the ICER were -877755 and 716385, 
respectively, based upon the 2.5th and 97.5th probability distribution percentiles. 
The isocontours in Figure 27b illustrate the regions that correspond to 10 regions 
of similar frequency of incremental cost and incremental effectiveness of strategy 2 vs. 
strategy 3. When the lines are close together, the magnitude of the slope is large, 
indicating steep variation. The willingness-to-pay line intersects the x and y axes at the 
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Figure 27. Incremental cost and effectiveness (ICE) scatter plot and isocontours graphs 
of strategy 2 vs. strategy 3. Strategy 2 = a CDR, a DD, a CT, and a CUS; Sfrategy 3 = a 
CDR, a DD, a CUS, and a CT. CDR = clinical decision rule; DD = D-dimer test; CT = 
computed tomography pulmonary angiography; CUS = compression ultrasonography; 
ALS = additional lives saved. 
Da3: At least strategy 3 will be more cost-effective than strategy 1, strategy 2, 
strategy 4, or strategy 5. 
This alternative decision is accepted. Strategy 3, comprising a CDR, a DD, a 
CUS, and a CT, with a cost of about $1,922,396 and an effectiveness level of 99.91767 
was the most cost-effective strategy (see Table 26). Additionally, sfrategy 3 dominates 
strategies 1, 2, and 4. Statistical results for the costs, effectiveness, and cost-effectiveness 
ratio of PE diagnostic sfrategy 3 are presented in Table 29. The DD, CUS, and CT 
branches of strategy 3 are presented in Figure 28. 
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Table 29 



























Note. PE = pulmonary embolism; Strategy 3 = a CDR, a DD, a CUS, and a CT. CDR = clinical decision 
rule; DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS = compression 
ultrasonography; C/E = cost-effectiveness ratio; ALS = additional lives saved. 
In strategy 3, the lowest cost was associated with a negative DD not requiring 
treatment, while the most expensive cost was incurred by the combination of a positive 
DD, a negative CUS, and a positive CT requiring treatment. The overall cost of a 
negative DD was $28 (c8). The overall cost of a positive DD followed by a positive CUS 
requiring treatment was $1,865 (c9). The overall cost of a positive DD, a negative CUS, 
and a positive CT requiring treatment was $2,986 (elO). The overall cost of a positive 
DD, a negative CUS, and a negative CT was $1,441 (cl 1). The DD, CUS, and CT 
branches of sfrategy 3 are presented in Figure 28. 
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Figure 28. Decision tree CEA model arm for PE diagnostic strategy 3. CEA = cost-
effectiveness analysis; PE = pulmonary embolism; Strategy 3 = a CDR, a CDR, a DD, a 
CUS, and a CT. CDR = clinical decision rule; DD = D-dimer test; CUS= compression 
ultrasonography; CT = computed tomography pulmonary angiography; Tr = treatment; 
ng = negative; p = positive; pn = probability; c = cost payoffs; e = effectiveness payoffs. 
Da4i At least strategy 4 will be more cost-effective than strategy 1, strategy 2, 
strategy 3, or strategy 5. 
This alternative decision is rejected. Sfrategy 4, comprising a CDR, a DD, a VQ, 
and a CUS, with a cost of $2,281,085 and an effectiveness level of 99.91518 was 
dominated by strategy 3 (see Table 26). Results for the costs, effectiveness, and cost-
effectiveness ratio of PE diagnostic strategy 4 are presented in Table 30. 
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Note. PE = pulmonary embolism; Strategy 4 = a CDR, a DD, a VQ, and a CUS. CDR = clinical decision 
rule; DD = D-dimer test; VQ = ventilation-perfusion lung scan; CUS = compression ultrasonography; C/E 
= cost-effectiveness ratio; ALS = additional lives saved. 
In strategy 4, the lowest cost was associated with a negative DD not requiring 
treatment, while the most expensive cost was incurred by a positive DD, a negative VQ, 
and a positive CUS requiring freatment. The overall cost of a negative DD was $28 (cl2). 
The overall cost of a positive DD followed by a positive VQ requiring treatment was 
$2,576 (cl3). The overall cost of a positive DD, a negative VQ, and a positive CUS 
requiring treatment was $2,868 (cl4). The overall cost of a positive DD, a negative VQ, 
and a negative CUS was $1,353 (cl5). The DD, VQ, and CUS branches of sfrategy 4 are 
presented in Figure 29. 
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Figure 29. Decision free CEA model arm for PE diagnostic sfrategy 4. CEA = cost-
effectiveness analysis; PE = pulmonary embolism; Strategy 4 = a CDR, a DD, a VQ, and 
a CUS. CDR = clinical decision rule; DD = D-dimer test; VQ = ventilation-perfusion 
lung scan; CUS= compression ultrasonography; Tr = treatment; ng = negative; p = 
positive; pn = probability; c = cost payoffs; e = effectiveness payoffs. 
The confidence ellipse on the cost-effectiveness plane in Figure 30a illustrates the 
region that contains 95% uncertainty surrounding cost and effectiveness comparators of 
strategy 4 vs. sfrategy 3. The dots in the confidence ellipse are located in the upper left 
(north-west) quadrant of the cost-effectiveness plane. This demonstrates that strategy 4 
was less effective and more costly than strategy 3. Thus, sfrategy 3 dominates strategy 
4.The lower and upper 95% confidence interval limits of the ICER were -665274 and 
19926, respectively, based upon the 2.5th and 97.5th probability distribution percentiles. 
The isocontours in Figure 30b illustrate the regions that correspond to 10 regions 
of similar frequency of incremental cost and incremental effectiveness of strategy 4 vs. 
strategy 3. When the lines are close together, the magnitude of the slope is large, 
indicating steep variation. The willingness-to-pay line intersects the x and y axes at the 
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Figure 30. Incremental cost and effectiveness (ICE) scatter plot and isocontours graphs 
of sfrategy 4 vs. strategy 3. Sfrategy 3 = a CDR, a DD, a CUS, and a CT; Sfrategy 4 = a 
CDR, a DD, a VQ, and a CUS. CDR = clinical decision rule; DD = D-dimer test; CT = 
computed tomography pulmonary angiography; CUS = compression ulfrasonography; 
VQ = ventilation-perfusion lung scan; ALS = additional lives saved. 
Das: At least strategy 5 will be more cost-effective than strategy 1, strategy 2, 
sfrategy 3, or strategy 4. 
This alternative decision is rejected. Sfrategy 5, comprising a CDR, a DD, a CT, a 
CUS, and a PA, with a cost of approximately $2,483.82 and an effectiveness level of 
99.91999 was a cost-effective strategy, while strategy 3 was the most cost-effective 
strategy (see Table 26). Results for the costs, effectiveness, and cost-effectiveness ratio of 
PE diagnostic strategy 5 are presented in Table 31. 
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Note. PE = pulmonary embolism; Strategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical 
decision rule; DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS = 
compression ultrasonography; PA = invasive pulmonary angiography; C/E = cost-effectiveness ratio; ALS 
= additional lives saved. 
In strategy 5, the lowest cost was associated with a negative DD not requiring 
treatment, while the most expensive cost was associated with a positive DD, a negative 
CT, a negative CUS, and a positive PA requiring treatment. The overall cost of a negative 
DD was $28 (cl6). The overall cost of a positive DD followed by a positive CT requiring 
treatment was $2,694 (cl7). The overall cost of a positive DD, a negative CT, and a 
positive CUS requiring treatment was $2,986 (cl8). The overall cost of a positive DD, a 
negative CT, a negative CUS, and a positive PA requiring treatment was $6,662 (cl9). 
The overall cost of a positive DD, a negative CT, a negative CUS, and a negative PA was 
$5,118 (c20). The DD, CT, CUS, and PA branches of sfrategy 5 are presented in Figure 
31. 
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Figure 31. Decision tree CEA model arm for PE diagnostic strategy 5. CEA = cost-
effectiveness analysis; PE = pulmonary embolism; Sfrategy 5 = a CDR, a DD, a CT, a 
CUS, and a PA. CDR = clinical decision rule; D-dimer test; CT = computed tomography 
pulmonary angiography; CUS= compression ultrasonography; PA = invasive pulmonary 
angiography; Tr = treatment; ng = negative; p = positive; pn = probability; c = cost 
payoffs; e = effectiveness payoffs. 
The confidence ellipse on the cost-effectiveness plane in Figure 32a illustrates the 
region that contains 95% uncertainty surrounding costs and effectiveness comparators of 
strategy 5 vs. strategy 3. The dots in the confidence ellipse are located in the upper right 
(north-east) quadrant of the cost-effectiveness plane. This indicates that strategy 5 was 
more effective and more costly than strategy 3, but its ICER was greater than the 
willingness-to-pay. Thus, sfrategy 3 is optimal. Overall, strategy 5 was a cost-effective 
strategy. The lower and upper 95% confidence interval limits of the ICER were 48523 
and 681970, respectively, based upon the 2.5th and 97.5th probability distribution 
percentiles. 
The isocontours in Figure 32b illustrate the regions that correspond to 10 regions 
of similar frequency of incremental cost and incremental effectiveness of strategy 5 vs. 
strategy 3. When the lines are close together, the magnitude of the slope is large, 
indicating steep variation. The willingness-to-pay line intersects the x and y axes at the 
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Figure 32. Incremental cost and effectiveness (ICE) scatter plot and isocontours graphs 
of strategy 5 vs. strategy 3. Sfrategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 5 = a 
CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule; DD = D-dimer test; 
CT = computed tomography pulmonary angiography; CUS = compression 
ultrasonography; PA = invasive pulmonary angiography; ALS = additional lives saved. 
Monte Carlo Simulation CEA Model Sensitivity Analysis Results 
Summary of Monte Carlo simulation sensitivity analysis results. 
Strategy 3 statistics were used as baseline data with a willingness-to-pay ranging 
from $.01 to $3,000 in a Monte Carlo simulation probabilistic sensitivity analysis within 
the CEA model. Figure 33 presents the results of this analysis as acceptability curves. 
Acceptability curves provide the uncertainty around cost-effectiveness and illustrate the 
probability that a sfrategy is cost-effective when compared with alternate strategies. The 
acceptability curve representing the optimal sfrategy demonstrates that the cost-
effectiveness probability of sfrategy 3 increased as the willingness-to-pay increased. 
The cost-effectiveness probability ranges determined for each strategy are as 
follows: (a) sfrategy 1, 0.0674 to 0.51006; (b) strategy 2, 0 to 0.00023; (c) strategy 3, 
0.45675 to 0.90172; (d) sfrategy 4, 0.03062 to 0.03322; and (e) strategy 5, 0 to 0.00003. 
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The sum of the cost-effective probabilities at each interval, i.e., the willing-to-pay 
amount, for the five PE diagnostic sfrategies is 1.00. The corresponding results at the 
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Figure 33. Acceptability curves with a willingness-to-pay from $.01 to $3,000. Strategy 1 
= a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS; Sfrategy 3 = a 
CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a CUS; Sfrategy 5 = 
a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule; DD = D-dimer test; 
CT = computed tomography pulmonary angiography; CUS= compression 
ulfrasonography; VQ = ventilation-perfusion lung scan; PA = invasive pulmonary 
angiography; ALS = additional lives saved. 
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Table 32 
Acceptability Curves with a Willingness-to-Pay from $.01 to $3,000 



































































Notes. Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS; Strategy 3 = a 
CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a CDR, a DD, a 
CT, a CUS, and a PA. DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS= 
compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive pulmonary 
angiography. 
Monte Carlo simulation of cost by strategy. 
Monte Carlo simulation (MCS) revealed sfrategy 1 cost values ranging from 
about $1,169.74 to $3,107.04. Within the first 10th percentile, the cost values were 
$1,472.47 or less, the median cost value was $1,893.73, and at or above the 90th 
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Figure 34. MCS of cost cumulative probability for strategy 1. Strategy 1 = a CDR, a DD 
and a CT; CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography 
pulmonary angiography. 
MCS revealed strategy 2 cost values ranging from about $1,633.05 to $3,632.07. 
Within the first 10th percentile, the cost values was $1,959.52 or less, the median cost 
value was $2381.89, and at or above the 90th percentile, the cost values were $3028.56 or 
greater (see Figure 35). 
Figure 35. MCS of cost cumulative probability for sfrategy 2. Sfrategy 2 = a CDR, a DD, 
a CT, and a CUS; CDR = clinical decision rule; DD = D-dimer test; CT = computed 
tomography pulmonary angiography; CUS = compression ultrasonography. 
MCS revealed strategy 3 cost values ranging from about $1,543.20 to $2,392.84. 
Within the first 10th percentile, the cost values was $1,759.13 or less, the median cost 
value was $1,911.07, and at or above the 90th percentile, the cost values were $2,106.78 
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Figure 36. MCS of cost cumulative probability for strategy 3. Strategy 3 = a CDR, a DD, 
a CUS, and a CT; CDR = clinical decision rule; DD = D-dimer test; CUS = compression 
ultrasonography; CT = computed tomography pulmonary angiography. 
MCS identified strategy 4 cost values ranging from about $1,870.05 to 
$2,725.04. Within the first 10th percentile, the cost values was $2,082.96 or less, the 
median cost value was $2,273.69, and at or above the 90th percentile, the cost values 
were $2,490.71 or greater (see Figure 37). 
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Figure 37. MCS of cost cumulative probability for strategy 4. Sfrategy 4 = a CDR, a DD, 
a VQ, and a CUS; CDR = clinical decision rule; DD = D-dimer test; CT = computed 
tomography pulmonary angiography; VQ = ventilation-perfusion lung scan; CUS = 
compression ultrasonography. 
MCS identified strategy 5 cost values ranging from about $1,667.69 to $3,671.55. 
Within the first 10th percentile, the cost values was $2,001.67 or less, the median cost 
value was $2,423.89, and at or above the 90th percentile, the cost values were $3,071.55 
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Figure 38. MCS of cost cumulative probability for sfrategy 5. Strategy 5 = a CDR, a DD, 
a CT, a CUS, and a PA; CDR = clinical decision rule; DD = D-dimer test; CT = 
computed tomography pulmonary angiography; CUS = compression ultrasonography; 
PA = invasive pulmonary angiography. 
Monte Carlo simulation of incremental cost and effectiveness by strategy. 
Incremental cost values were generated from a Monte Carlo simulation (MCS) 
independently comparing the sfrategy 3 statistical data set against the data set of each 
other sfrategy. The incremental cost values generated when PE strategy 1 was compared 
to PE strategy 3, ranged (in dollars) from -614.82 to 919.34. Probability levels increased 
as incremental dollar cost increased with the highest attained probability achieved at 
.11181 (-$140), after which probability decreased. The probability of attaining 
incremental cost values (in dollars) of-614, -300, -220, 100, 260, 340, 420, 580, 740, and 
919 was .07082, .10170, .08630, .07047, .06074, .05129, .03165, .01319, and .00005, 
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Incremental Cost Figure 39. MCS incremental cost probability of strategy 1 vs. strategy 3. Strategy 1 = a 
CDR, a DD and a CT; Strategy 3 = a CDR, a DD, a CUS, and a CT. CDR = clinical 
decision rule; DD = D-dimer test; CT = computed tomography pulmonary angiography; 
CUS = compression ultrasonography. 
As Figure 40 indicates, the incremental cost values generated when PE strategy 2 
was compared to PE sfrategy 3, ranged (in dollars) from -74.66 to 1,374.52. Probability 
levels increased as incremental dollar cost increased with the highest attained probability 
achieved at .10002 ($340), after which probability decreased. The probability of attaining 
incremental cost values (in dollars) of 74, 130, 270, 410, 550, 690, 900, 1,180 and 1,374 
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Incremental Cost Figure 40. MCS incremental cost probability of sfrategy 2 vs. strategy 3. Strategy 2 = a 
CDR, a DD, a CT, and a CUS; Strategy 3 = a CDR, a DD, a CUS, and a CT. CDR = 
clinical decision rule; DD = D-dimer test; CT = computed tomography pulmonary 
angiography; CUS = compression ultrasonography. 
The incremental cost values generated when PE sfrategy 4 was compared to PE 
sfrategy 3, ranged (in dollars) from -384.36 to 979.89. Probability levels increased as 
incremental costs increased with the highest attained probability achieved at .13889 
($380), after which probability decreased. The probability of attaining incremental cost 
values (in dollars) of-384, 100, 170, 310, 450, 590, 730, 870, and 979 were .00001, 
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Figure 41. MCS incremental cost probability of sfrategy 4 vs. strategy 3. Strategy 3 = a 
CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a CUS. CDR = 
clinical decision rule; DD = D-dimer test; CT = computed tomography pulmonary 
angiography; CUS = compression ulfrasonography; VQ = ventilation-perfusion lung 
scan. 
The incremental cost values generated when PE strategy 5 was compared to PE 
strategy 3, ranged (in dollars) from -40.35 to 1,414.90. Probability levels increased as 
incremental costs increased with the highest attained probability achieved at. 10020 
($370), after which probability decreased. The probability of attaining incremental cost 
values (in dollars) of-40, 160, 230, 510, 580, 790, 1,000, 1,280 and 1,414 were .00001, 
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Figure 42. MCS incremental cost probability of strategy 5 vs. strategy 3. Strategy 3 = a 
CDR, a DD, a CUS, and a CT; Sfrategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR 
= clinical decision rule; DD = D-dimer test; CT = computed tomography pulmonary 
angiography; CUS = compression ultrasonography; PA = invasive pulmonary 
angiography. 
An MCS generated incremental effectiveness values when PE strategy 1 was 
compared to PE sfrategy 3. Effectiveness, which is measured as additional lives saved 
(ALS), ranged from -.30351 to .02074. Probability increased as incremental effectiveness 
increased, with the highest attained probability of .20034 and effectiveness value of-.13, 
after which probability decreased. The probabilities of attaining incremental effectiveness 
values of-0.31, -0.25, -0.23, -0.15, -0.09, -0.05, -0.01, 0.01, and 0.02 were .00001, 
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Figure 43. MCS incremental effectiveness probability of sfrategy 1 vs. strategy 3. 
Strategy 1 = a CDR, a DD and a CT; Strategy 3 = a CDR, a DD, a CUS, and a CT. CDR 
= clinical decision rule; DD = D-dimer test; CT = computed tomography pulmonary 
angiography; CUS = compression ultrasonography. 
An MCS generated incremental effectiveness values when PE strategy 2 and 3 
were analyzed. Effectiveness, which is measured as additional lives saved (ALS), ranged 
from -0.02783 to 0.016424. Probability increased as effectiveness increased, with the 
highest attained probability of .15370 and incremental effectiveness value of-0.006, after 
which probability decreased. The probabilities of attaining incremental effectiveness 
values of-.028, -.016, -.012, -.01, -.004, .01, .012, .014, and .018 were .00001, .01472, 
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Figure 44. MCS incremental effectiveness probability of strategy 2 vs. strategy 3. 
Strategy 2 = a CDR, a DD, a CT, and a CUS; Strategy 3 = a CDR, a DD, a CUS, and a 
CT. CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography 
pulmonary angiography; CUS = compression ultrasonography. 
An MCS generated incremental effectiveness values when PE sfrategies 4 and 3 
were analyzed for effectiveness. Effectiveness, which is measured as additional lives 
saved (ALS), ranged from -0.00719 to 0.001929. Probability increased as incremental 
effectiveness increased, with the highest attained probability of .19576 and incremental 
effectiveness value of .0022, after which probability decreased. The probabilities of 
attaining incremental effectiveness values of .00719, -.0052, -.0047, -.0037, -.0012, -
.0007, .0008, .0018, and .001929 were .00001, .00312, .01098, .0691, .11702, .06513, 
.00257, .00009 and .00001, respectively (see Figure 45). 
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Figure 45. MCS incremental effectiveness probability of strategy 4 vs. sfrategy 3. 
Strategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a 
CUS. CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography 
pulmonary angiography; CUS = compression ulfrasonography; VQ = ventilation-
perfusion lung scan. 
An MCS generated incremental effectiveness values when PE strategies 5 and 3 
were analyzed for effectiveness. Effectiveness, which is measured as additional lives 
saved (ALS), ranged from -0.00031 to 0.005045. Probability increased as incremental 
effectiveness increased, with the highest attained probability of 0.18501 and effectiveness 
value of 0.0026, after which probability decreased. The probabilities of attaining 
incremental effectiveness values of-.00031, .0005, .0014, .0023, .0035, .0041, .0044, 
.0047, and .0053 were .00001, .00139, .04456, .1819, .05099, .00717, .00162, .00052, 
and .00002, respectively (see Figure 46). 
Figure 46. MCS incremental effectiveness probability of strategy 5 vs. strategy 3. 
Strategy 3 = a CDR, a DD, a CUS, and a CT; Sfrategy 5 = a CDR, a DD, a CT, a CUS, 
and a PA. CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography 
pulmonary angiography; CUS = compression ultrasonography; PA = invasive pulmonary 
angiography. 
Monte Carlo simulation of D-dimer test, computed tomography pulmonary 
angiography, compression ultrasonography, ventilation-perfusion lung scan, 
invasive pulmonary angiography, and treatment costs. 
As graphed in Figure 47, MCS uncovered DD cost values ranging from $25.60 to 
$33. Probability increased as DD cost increased, with the highest attained probability of 
.417 at a cost of $28, after which probability decreased. Probabilities for the costs (in 
dollars) of 26, 30, 32, and 33 were .062, .333, .166, and .021, respectively. 
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Figure 47. Probability distribution of D-dimer test (DD) cost. 
As graphed in Figure 48, the MCS identified CT cost values ranging from $276 to 
$2,374. Probability increased as CT cost increased, with the highest attained probability 
of .093 at a cost of $800, after which probability decreased. Probabilities for the costs (in 
dollars) of 276, 400, 600, 1,000, 1,400, 1,800, 2,000, 2,200, and 2,374 were .001, .017, 
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Figure 48. Probability distribution of computed tomography pulmonary angiography 
(CT) cost. 
MCS revealed CUS cost values ranging from $137 to $431. Probability increased 
as CUS cost increased, with the highest attained probability of. 128 at a cost of $320, 
after which probability decreased. Probabilities for the costs (in dollars) of 137, 180, 220, 
260, 300, 340, 360, 400 and 431 were .001, .027, .058, .089, .124, .109, .066, .045, and 
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Figure 49. Probability distribution of compression ulfrasonography (CUS) cost. 
MCS uncovered VQ cost values ranging from $612 to $1,434. Probability 
increased as VQ cost increased, with the highest attained probability of .160 at a cost of 
$920, after which probability decreased. Probabilities for the costs (in dollars) of 612, 
700, 770, 840, 1,050, 1,190, 1,330, 1,400 and 1,434 were .001, .025, .059, .094, .152, 










0 •) 1 1 I I—"T 1 1 1 1 i I 
o o o o o o o o o o o o o o o o o o o o o o 
p ^ ^ t « - i o o L n r M c n u 5 r o o r ~ - ^ j - r - i o o L n r M a i i D r o o r ^ 
^ H r M r M m ^ - ^ - L O i o r ^ r ^ o o c n C T i O T H ' H f M r o ^ - ^ -
iH r-( «H *H <H TH r-t 
Cost 
Figure 50. Probability distribution of ventilation-perfusion lung scan (VQ) cost. 
MCS revealed PA cost values ranging from $1,072 to $8,370. Probability 
increased as PA cost increased, with the highest attained probability of .108 at a cost of 
$2,000, after which probability decreased. Probabilities for the costs (in dollars) of 1,200, 
1,600, 2,400, 3,200, 4,000, 5,200, 6,000, 7,200 and 8,370 were .004, .071, .099, .086, 
.072, .055, .041, .023, and .003, respectively (see Figure 51). 
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Figure 51. Probability distribution of invasive pulmonary angiography (PA) cost. 
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A Monte Carlo simulation unveiled treatment cost (Tr) values ranging from 
$1,450 to $1,639. Probability increased as treatment cost increased, with the highest 
attained probability of .638 at a cost of $1,600, after which probability decreased. 
Probabilities for the treatment costs (in dollars) of 1,520 and 1,639 were .274 and .088, 
respectively (see Figure 52). 
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Figure 52. Probability distribution of treatment (Tr) cost. 
One-Way Sensitivity Analysis 
The DD cost in the one-way sensitivity analysis varied from $1 to $101, with all 
other factors (parameters) held constant. The analysis revealed that sfrategies 3 and 5 
were cost-effective at each amount level (i.e., $1, $31, $71, and $101). Strategy 3 was the 
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c) DDcost=$71 d)DD cost =$101 
Figure 53. One-way sensitivity analysis on D-dimer test cost varying from $1 to $101. 
Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS; 
Strategy 3 = a CDR, a DD, a CUS, and a CT; Sfrategy 4 = a CDR, a DD, a VQ, and a 
CUS; Sfrategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule; 
DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS = 
compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive 
pulmonary angiography; ALS = additional lives saved. 
Figure 54 reveals that the CT cost in the one-way sensitivity analysis varied from 
$100 to $3,100, with all other factors held constant. This analysis revealed that strategies 
3 and 5 were cost-effective at each amount level (i.e., $100, $700, $1,600, and $3,100). 
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c) CT cost = $1,600 d) CT cost = $3,100 
Figure 54. One-way sensitivity analysis on CT cost varying from $100 to $3,100. 
Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS; 
Strategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a 
CUS; Strategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule; 
DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS = 
compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive 
pulmonary angiography; ALS = additional lives saved. 
Figure 55 indicates that the CUS cost in a one-way sensitivity analysis varied 
from $50 to $1,050, with all other factors held constant. The analysis revealed that 
strategies 3 and 5 were cost-effective at each amount level (i.e., $50, $450, $750, and 
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c) CUScost=$750 d) CUS cost = $1,050 
Figure 55. One-way sensitivity analysis on CUS cost varying from $50 to $1,050. 
Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS; 
Strategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a 
CUS; Sfrategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule; 
DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS = 
compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive 
pulmonary angiography; ALS = additional lives saved. 
A one-way sensitivity analysis revealed that the costs of VQ testing varied from 
$100 to $2,100 with all other factors held constant. Strategies 3 and 5 were identified as 
cost-effective at each amount level (i.e., $100, $700, $1,500, and $2,100). Strategy 3 
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c) VQ cost = $ 1,500 d) VQ cost = $2,100 
Figure 56. One-way sensitivity analysis on VQ cost varying from $100 to $2,100. 
Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS; 
Strategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a 
CUS; Strategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule; 
DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS = 
compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive 
pulmonary angiography; ALS = additional lives saved. 
Results from the one-way sensitivity analysis of the cost of PA testing indicated 
cost variability from $100 to $9,100, with all other factors held constant. The analysis 
revealed that strategies 3 and 5 were cost-effective at each amount level (i.e., $100, 

$1,900, $7,300, and $9,100). Strategy 3 was the most cost-effective strategy and 
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c) PA cost = $7,300 d) PA cost = $9,100 
Figure 57. One-way sensitivity analysis on PA cost varying from $100 to $9,100. 
Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS; 
Sfrategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a 
CUS; Strategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule; 
DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS = 
compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive 
pulmonary angiography; ALS = additional lives saved. 
The examination of PE freatment costs using a one-way sensitivity analysis 
showed that the cost varied from $100 to $4,100, with all other factors held constant. The 
analysis revealed that strategies 3 and 5 were cost-effective at each amount level (i.e., 
$100, $1,700, $3,300, and $4,100). Strategy 3 was the most cost-effective strategy and 
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c) Tr cost = $3,300 d) Tr cost = $4,100 
Figure 58. One-way sensitivity analysis on treatment cost varying from $100 to $4,100. 
Sfrategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS; 
Strategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a 
CUS; Strategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule; 
DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS = 
compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive 
pulmonary angiography; ALS = additional lives saved. 
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Two-Way Sensitivity Analysis 
A two-way sensitivity analysis was employed to examine the impact of CEA 
results on simultaneous changes in the costs of two variables. This analysis revealed that 
strategy 3 was the dominant sfrategy for any pair of costs, indicating that it was the most 
cost-effective strategy. The results were robust for all imaging test changes. Specifically, 
the CUS cost varied from $50 to $1,050, the CT cost varied from $100 to $3,100, the VQ 
cost varied from $100 to $2,100, the PA cost varied from $100 to $9,100, and the 
treatment (Tr) cost varied from $100 to $4,100. The two-way analyses of the CUS and 
the CT cost, the CUS and the VQ cost, the CUS and the PA cost, and the CUS and the 
treatment cost are presented in Figure 59. 
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Figure 59. Two-way sensitivity analysis. Strategy 1 = a CDR, a DD and a CT; Strategy 2 
= a CDR, a DD, a CT, and a CUS; Strategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 
4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a CDR, a DD, a CT, a CUS, and a PA. 
CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography pulmonary 
angiography; CUS = compression ultrasonography; VQ = ventilation-perfusion lung 
scan; PA = invasive pulmonary angiography; Tr = freatment. 
Three-Way Sensitivity Analysis 
A three-way sensitivity analysis examined the impact of CEA results on 
simultaneous changes in the costs of three variables. This analysis revealed that strategy 3 
was the dominant strategy for any group of costs, indicating that it was the most cost-
effective strategy. The results were robust for all imaging test changes. Particularly, the 
DD cost varied from $1 to $100, CUS cost varied from $50 to $1,050, the CT cost varied 
from $100 to $3,100, the VQ cost varied from $100 to $2,100, the PA cost varied from 
$100 to $9,100, and the treatment (Tr) cost varied from $100 to $4,100. The three-way 
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Figure 60. Three-way sensitivity analysis. Sfrategy 1 = a CDR, a DD and a CT; Strategy 
2 = a CDR, a DD, a CT, and a CUS; Sfrategy 3 = a CDR, a DD, a CUS, and a CT; 
Strategy 4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a CDR, a DD, a CT, a CUS, 
and a PA. CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography 
pulmonary angiography; CUS = compression ulfrasonography; VQ = ventilation-
perfusion lung scan; PA = invasive pulmonary angiography. 
CHAPTER 5 
SUMMARY 
This chapter presents the summary of the findings regarding parameter 
estimates, cost-effectiveness analyses, sensitivity analyses, limitations, and implications 
for practice and research. Differences between the research findings and those retrieved 
from the literature are addressed. Findings from the Monte Carlo simulation (MCS) 




This research suggests that there is a linear increase in the adjusted-for-inflation 
direct costs. This study has demonstrated that frend line equations strongly support a 
linear increase in the adjusted-for-inflation direct costs, with high r values indicating that 
more than 98% of the variation in the models is explained by these equations (see Tables 
10 through 15). 
Applying triangular distributions in a CEA to estimate expected direct cost values 
of PE diagnostic tests addresses variability in data retrieved from the literature, resolves 
uncertainty, and eliminates error in the assigned baseline values. This is a possible 
explanation for the differences between the expected cost values applied in the study and 
those identified in the literature. Consequently, by applying triangular distributions to 
estimate diagnostic test costs, the differences reported in the literature were combined 
(see Table 16 and Figures 9 through 20). All test and treatment costs were adjusted based 
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upon the estimations: DD ($28); CT ($1,121); CUS ($292); VQ lung scan ($1,003); PA 
($3,676); and PE freatment cost for one year ($1,545). 
The findings of this dissertation suggest that applying effectiveness based upon 
strategy failure rates to detect PE is an accurate way to address effectiveness payoff 
values in a CEA model. The use of y distributions in a CEA assists with estimating 
expected strategy failure rates of the investigated PE diagnostic tests, addresses 
variability in data retrieved from the literature, resolves uncertainty, and eliminates error 
in the assigned baseline values. This may explain why the expected strategy failure rates 
applied in this study differ from those identified in the literature. Subsequently, by 
applying y distributions to estimate PE diagnostic strategy failure rates, the differences 
reported in the literature were merged (see Table 19): strategy 1 (.576667); strategy 2 
(1.099999); strategy 3 (.546667); strategy 4 (1.004999); and strategy 5 (.72500). 
The use of y disfributions facilitates the estimating of sensitivity and specificity 
values of PE diagnostic D-dimer and imaging tests data obtained from the literature (see 
Tables 22 through 24). The application of y distributions in a CEA to estimate expected 
sensitivity and specificity values of the investigated PE diagnostic tests addresses 
variability in the data retrieved from the literature, resolves uncertainty, and eliminates 
error in the assigned baseline values. It might explain why the expected sensitivity and 
specificity values applied in this study differ from those identified in the literature. By 
applying y distributions to estimate PE diagnostic test sensitivity, the differences reported 
in the literature for sensitivity were combined: DD (95.174%); CT (88.112%); CUS 
(89.95%); VQ lung scan (82.775%); and PA (97.25%). Consequently, by applying y 
disfributions to estimate PE diagnostic test specificity, the differences reported in the 
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literature were combined: DD (47.775%); CT (94.569%); CUS (94.900%); VQ lung scan 
(90.5%); PA (97.0%). 
The findings of this thesis further suggest that using a series of Bayes's theorem 
applications to estimate expected event probability values of the PE diagnostic tests based 
upon test sensitivities and specificities, addresses the accuracy of a given test. 
Consequently, in strategy 1 the accuracy of the CT is dependent upon the preceding DD 
results. In sfrategy 2, the accuracy of the CT is dependent upon the preceding DD results 
and the accuracy of the CUS is dependent upon the results of the preceding CT. In 
strategy 3, the accuracy of the CUS is dependent upon results from the preceding DD and 
the accuracy of the CT is dependent upon the preceding CUS. In strategy 4, the accuracy 
of the VQ lung scan is dependent upon the results from the preceding D-dimer test and 
the accuracy of the CUS is dependent upon a preceding VQ lung scan. In strategy 5, the 
accuracy of the CT is dependent upon the results from the preceding D-dimer test, the 
accuracy of the CUS is dependent upon the preceding CT, and the accuracy of the PA is 
dependent upon the preceding CUS (see Figure 21). 
Cost-Effectiveness Analysis. 
The cost-effectiveness analysis results demonstrated that strategy 3, comprising 
CDR, a DD, a CUS, and a CT, was the most cost-effective sfrategy and dominated 
strategies 1, 2 and 4. Additionally, strategy 5, comprising a CDR, a DD, a CT, a CUS, 
and a PA was a cost-effective sfrategy. 
There is no assumption in this analysis about the different types of imaging tests. 
Imaging tests were clearly used in the model based upon the corresponding cost and 
effectiveness values as they were estimated by the statistical methodology of the analysis. 
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The use of a CUS after a high clinical probability or a positive D-dimer test is an 
appropriate, efficient, and safe approach suggested by several studies (Elias et al., 2005; 
Hull et al., 2001; Perrier et al., 2004; Righini et al., 2008; Van Erkel et al., 1999). The use 
of a CT after a high clinical probability or a positive D-dimer test and a negative CUS is 
considered an appropriate, efficient, and safe approach proposed by several studies (Elias 
et al., 2005; Perrier et al., 2004; Righini et al., 2008). 
Sensitivity Analysis. 
The results of the MCS probabilistic sensitivity analysis were robust for a number 
of disfributions regarding PE diagnostic test costs, effectiveness, sensitivities, 
specificities, and event probabilities. Consequently, the sensitivity analysis results 
demonstrated that with a willingness-to-pay from $.01 to $3,000 strategy 3 demonstrated 
the highest probability of being cost-effective in comparison to the other strategies 
examined (see Table 32 and Figure 33). 
The results of this investigation were robust over an extensive range of one-way, 
two-way, and three-way deterministic sensitivity analyses regarding PE diagnostic test 
costs (see Figures 53 through 60). The one-way sensitivity analysis revealed that strategy 
3 remained the most cost-effective sfrategy in comparison to strategies 1,2,4, and 5 
when applying the diagnostic test and treatment costs in various combinations. 
Specifically, the variation of D-dimer test costs from $1 to $101 revealed that both 
sfrategy 3 and strategy 5 remained cost-effective. The variation of CT costs from $100 to 
$3,100 revealed that both strategy 3 and strategy 5 remained cost-effective. The variation 
of CUS costs from $50 to $1,050 revealed that both strategy 3 and sfrategy 5 remained 
cost-effective. The variation of VQ lung scan costs from $100 to $2,100 revealed that 
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both strategy 3 and strategy 5 remained cost-effective. The variation of PA costs from 
$100 to $9,100 revealed that both strategy 3 and sfrategy 5 remained cost-effective. The 
variation of PE treatment cost from $100 to $4,100 revealed that both strategy 3 and 
strategy 5 remained cost-effective. In all cases for each variation, strategy 3 dominated 
strategies 1, 2, and 4. 
Implications for Practice and Research 
This research contributed to theory, methodology, and medical decision-making 
by exploring the boundaries of a complex medical diagnostic system, addressing 
uncertainty, and decision theory; providing a method specifically designed to assist 
medical decision-making under uncertainty; and assessing PE cost-effective strategies. 
The ability to determine the cost-effectiveness of diagnostic sfrategies may prove to be a 
valuable health policy planning tool at the national, state, or local level as well as for 
providers of health insurance programs. It also may prove vital for saving resources 
within a limited health budget, especially for countries facing deficit problems and/or a 
financial crisis such as Greece and Portugal (see IMF, 2011; OECD, 2010), or for smaller 
countries experiencing problems related to their occupation by foreign troops; for 
example, Cyprus (see Eleftheriou, 2009; IMF, 2011). 
This thesis advocates for a clinical decision rule and a D-dimer test as a component of 
any PE diagnostic strategy. Therefore, an extensive use of D-dimer testing is 
recommended by this analysis. The increase in D-dimer test frequency will result in a 
substantial cost reduction of the overall PE diagnostic testing cost due to the decreased 
use of imaging tests. This shift in imaging test usage is valuable to low and intermediate 
clinical decision rule categories. The findings of this research also suggest that applying 
triangular and y distributions in a CEA facilitates the assessment of parameter estimates, 
addresses variability in data retrieved from the literature, resolves uncertainty, and 
eliminates error in the assigned baseline values. Further research is required to confirm 
these findings in a prospective study that establishes assumptions about the types of D-
dimer and imaging tests performed. Finally, further research should be conducted to 
evaluate whether the methods implemented in this study are applicable for other diseases, 
such as for lung and cardiovascular diseases. 
Conclusion 
In conclusion, this CEA research suggests that, among the five PE diagnostic 
strategies investigated, the most cost-effective strategy appears to be strategy 3, 
comprising a CDR, a DD, a CUS, and a CT. An initial diagnosis should begin with a 
CDR and a DD since a negative DD rules out clinically suspected PE. If a positive DD is 
determined, then the diagnosis of PE should be investigated by performing a CUS. In 
patients with a positive CUS, a treatment should be applied; patients with a negative or 
nondiagnostic CUS require further investigation employing a CT. Alternatives to this 
approach such as strategy 5, which is composed of a CDR, a DD, a CT, a CUS, and a PA, 
appears to be a cost-effective, but it is a more expensive sfrategy than strategy 3. This 
strategy includes PA, which is an invasive test. Strategy 1, which consists of a CDR, a 
DD, and a CT, is a highly effective non-invasive technique but appears to be more 
expensive than strategy 3. Future work is needed to validate these findings in a 
prospective clinical trial before the delivery of a clinical recommendation. 
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